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Summary 
The covalent binding of chemical carcinogens to DNA of mammalian organs 
is expressed per unit dose, and a 'Covalent-Binding Index', CBI, is defined. CBI 
for various carcinogens span over 6 orders of magnitude. A similar range is ob-
served for the carcinogenic potency in long-term bioassays on carcinogenicity. 
For the assessment of a risk from exposure to a carcinogen, the total DN A 
darnage can be estimated if the actual dose is also accounted for. 
A detailed description is given for planning and performing a DNA-binding 
assay. 
A complete literature survey on DNA binding in vivo (83 compounds) is 
given with a calculation of CBI, where possible, 153 compounds are listed 
where a covalent binding to any biological macromolecule has been shown in 
vivo or in vitro. Recent, so far unpublished findings with aflatoxin Mh macro-
molecule-bound aflatoxin Bh ·diethylstilbestrol, and 1,2-epithiobutyronitrile 
are included. 
A comparison of CBI for rat-liver DNA with hepatocarcinogenic potency 
reveals a surprisingly good quantitative correlation. 
Refinements for a DN A-binding assay are proposed. Possibilities and Iimita-
tions in the use of D NA binding in chemical carcinogenesis are discussed 
extensively. 
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1. lntroduction 
1.1. Mechanism of action of organic carcinogens 
The immense structural variety of organic chemical carcinogens [as reviewed 
in 161, 211] posed, for a long time, great difficulties in the understanding of 
the mechanism of carcinogenic action. Today, there is substantial evidence for 
a uniform sequence of events goveming the process of tumor formation after 
exposure to an organic carcinogen. This process is shown schematically in Fig. 
1 and has been summarized before [69,91,178]. 
Most carcinogenic chemieals can undergo a covalent binding to biological 
macromolecules either by themselves or after metabolic activation to a chemi-
cally reactive form, the so..called ultimate carcinogen. This binding to a biologi-
cal macromolecule can Iead to heritable cellular damage, most directly if the 
target is DNA. If such DNA darnage is not properly repaired before the cell 
divides, a mutation can be produced and form the basis for a cell transforma-
tion and possible development into a tumor. 
Besides this so..called "genotoxic" mode of reaction, with D NA as target 
molecule, the chemically reactive forms of the carcinogens interact at the same 
time with various RNAs and proteins. Some of these macromolecules play an 
important role in cellular growth control or DNA replication so that "epi-
genetic" possibilities for the mechanism of tumor initiation cannot be excluded. 
There is, however, increasing evidence that binding to DNA correlates better 
with tumor incidence than does binding to RNA or protein (section 2.1). 
The general process of the metabolic activation involves oxidation of the car-
cinogen to electrophilic derivatives by the cellular mixed function oxidases 
which are located in the endoplasmic reticulum and, with much less activity, 
in the nuclear envelope. A natural function of this complex series of enzymes 
appears to be the conversion of hydrophobic chemieals into hydrophilic, easily 
excreted compounds. Thus, it is an irony of nature that an enzyme system 
apparently designed for detoxification may also be responsible for the activa-
tion of chemically inert compounds into reactive carcinogens. Fig. 2 shows a 
Intake of chem1call 
inert compound 
Excretion 
Deactivation and excretion 
L---__,;.....;....;.,.....::...;;.;;.,;..;;.._----' (Rearrangement, reaction wit 
water or non·critical target) 
IIT!IIune surveillance 
Fig. 1. Sequence of events in the cbemical induction of a tumor. From the left to the center: Intake of 
the chemical. From the center to the right: Reactions of the chemical or of the organiBm which do not 
Iead to heritable damage or a tumor. From top to bottom: Stepwise progresston of the tumor. 
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Fig, 2. Selection of organic carcinogens of different chemical classes with a known or strongly suspected 
electrophilic center (arrow) or chemically reactive derivative (on the right). the ultimate carcinogen. E, 
enzymatic activation required; 1, methyl methaneSulpbonate; 2, 1,2,3,4-diepoxybutane; 3, ß-propiolac-
tone: 4, a sulphur mustard~ 5, carbon tetrachloride; 6, a polycyclic aromatic hydrocarbon (the reactive 
metabolite shown is k.nown from benzo[a]pyrene); 7. 2-a.cetylaminofiuorene; 8, 1,2-dimethylbydrazine; 
9, N,N-dimethylnitrosamine; 10, aßatoxin 81. 
few examples of chemical carcinogens together with the known or strongly 
suspected electrophilic, chemically reactive metabolites. This aspect of metab-
olic activation has been reviewed extensively [161,282] and is also a topic of 
the other reviews cited in this chapter. 
A number of compounds like antioxidants, enzyme-inducing or enzyme-
inhibitory agents have an influence on the activation/inactivation pathways in 
the metabolism of chemical carcinogens [ 281]. Such compounds have been 
shown to alter the tumor incidence and the extent of covalent binding of car-
cinogens to cellular macromolecules. and the results are discussed in chapter 5. 
After these initiathig events in tumor induction there is a necessary and long 
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period of "promotion". A variety of chemieals act at this stage, on the mecha-
nisms which govern the side reactions in Fig. 1 between D NA binding and the 
manifestation of the tumor. This process has been reviewed [88,249], and sec-
tion 6.1 sumniarizes the various possibilities for an interference of chemieals 
with the process of tumor promotion. 
In addition to the carcinogenicity by organic chemicals, there are other 
causes of cancer; carcinogenic metals, other inorganic carcinogens, any form of 
radiation, the influence of oncogenic viruses. None of these topics will be dis-
cussed in this review. 
1.2. Short-term tests for the detection of chemical carcinogens. Quantitative 
carcinogenesis 
Most short-terrn tests for carcinogenicity measure one of the steps shown in 
Fig. 1. These are, among others, reaction with nucleic acids or proteins, DNA-
repair synthesis, mutagenesis, various chromosome damages, cytological altera-
tions, in vitro cell transformation, tera.togenesis, or accelerated tumor forma-
tion. They have been reviewed before [19,77 ,94,180,258] and have also been 
compared with each other [214). Many of these systems do not deal with 
intact mammalian organisms but use bacteria or cells in culture. The well-
known "Ames test", e.g., is based upon the measurement of backmutations of 
Salmonella of selected strains after incubation with the test compound [2]. 
The metabolic activation is performed by microsomes of mammalian organs 
tagether with cofactors. This is necessary because of the very limited ability of 
Salmonella for drug metabolism. 
The Ames test is able to recognize qualitatively about 90% of the known car-
cinogens as mutagens. Among the 10% false negatives are some very potent car-
cinogens of the dimethylamino and hydrazine type as well as a nurober of halo-
genated compounds. The reason for their ineffectiveness has been discussed [ 3, 
66,173], and it has emerged that the metabolic activation in the bacterial incu-
bation is insufficient for N-demethylations or dehalogenations. By varying the 
experimental conditions a slight improvement has been achieved but it still 
seems that, for the above-mentioned chemical classes, the Ames test is not the 
appropriate short-term test. 
Another point of concem is the lack of the quantitative aspect in the inter-
pretation of the Ames test and of other in vitro tests. A discussion about a 
quantification of carcinogenicity of chemieals [ 17 5] is now developing 
although it should have been obvious for a long time that some carcinogens are 
morepotent than others. From long-term bioassays it can easily be calculated 
that the range of carcinogenic potency spans about 6 orders of magnitude if 
we compare the dose per kg animal and day which is needed to induce a spe-
cific tumor in 50% of the animals within their life span. This dose ranges from 
less than one microgram/kg · day for aflatoxin B1 to many grams for saccharin. 
A look at the mutagenicity data from the Ames test shows that this quanti-
tative aspect can barely be considered even within a class of related com-
pounds. The polycyclic hydrocarbons, e.g., which can be well studied in the 
Ames test, show increasing mutagenicity in the order of dibenz[a,h ]anthra-
cene < 7 ,12--dimethylbenz[a]anthracene < 3-methylcholanthrene <. benzo[a]-
pyrene < dibenz[a,c]anthracene [172] although their effect on mouse-skin 
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tumor formation increases in the following order: dibenz[a,c]anthracene < 
dibenz[a,h]anthracene < benzo[a]pyrene < 3-methylcholanthrene < 7 ,12-di-
methylbenz[a]anthracene [98]. 
Theseproblems of incomplete metabolic activation and Iack of quantitative 
correlation have been discussed here with respect to the Ames test only, but 
this could also have been done with many other in vitro systems. This is the 
reason why we have chosen an intact mammalian organism as the experimental 
basis for another possible short-term experiment, the covalent binding of 
chemieals to biological macromolecules. This test detected a number of Ames-
negative carcinogens and provides a basis for a quantitative assessment of car-
cinogenic potency if DNA is taken as target. 
1.3. Covalent binding of chemical carcinogens to biological macromolecules 
The first experiment on in vivo binding of a chemical to a biological macro-
molecule was reported by the Millers in 1947 with 4-dimethylaminoazobenzene 
in rat liver [ 177]. Since then, more than 150 compounds have been shown to 
undergo a covalent binding to biological macromolecules in vivo or in vitro and 
a nurober of reviews are available: a recent and very extensive one by Lawley 
[139], others by Irving (103], Sarma [228] and, for N-nitroso compounds 
only, by Lijinsky [149]. Brookes has published two classical short reviews [22, 
24] and a short discussion on the importance of DNA as the most critical target 
for a covalent binding [ 2 5]. 
The easiest way to study the reactivity of a chemical with a biological macro-
molecule involves an in vitro incubation of radiolabelled chemical with protein 
in the presence of some activating enzyme preparation [274]. In vivo, the 
binding is not so easily detected because the high in vitro concentrations 
cannot be achieved. 
Protein binding is in most cases higher than binding to nucleic acids because 
of the higher intracellular concentrations of protein and their closeness to the 
site of activation. In addition, the sulphur-containing amino acids are very good 
nucleophiles and, therefore, very good trapping agents for the electrophilic ulti-
mate carcinogens. Unfortunately, protein binding does not give any quantita· 
tive answer to the carcinogenicity of a chemical but it shows at least that a 
reactive metabolite can be formed. This will always be a warning sign because, 
in principle, the binding to DNA could have occurred but the Iimit of detection 
was perhaps not low enough. 
Some target atoms on the nucleic acid and proteins are shown in Fig. 3. 
These include all the more or less nucleophilic centers in nucleotides and amino 
acids. The chemical reactivity of these biological targets has been discussed 
before [135,202,244,245] and the biological significance of the binding of a 
carcinogen to one or the other nucleophilic center will be discussed in chapter 
4. ' 
In the last section it has been pointed out that the metabolic activation in 
most in vitro short-term tests is different from the in vivo situation so that 
false-negative results are obtained with some important classes of carcinogens. 
The positive results that were obtained in a covalent binding assay in vivo with 
most of these !alse-negatives make it worthwhile to thoroughly evaluate this 
interaction as a possible carcinogenicity test. 
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Fig. 3. Nucleophilic atoms of components of biological macromolecules. The most reactive (not neces-
sarily most critical) target atoms of DNA and protein are indicated with an arrow. Analogous for RNA. 
Top, thymine-1denine; cytosine-guanine. Bottom, cysteine (also as cystine), methionine, histidine, 
tyrosine. Not shown, DNA phosphate. 
2. Covalent binding to DNA 
2.1. Introduction. In uivo uersus in vitro 
The first experiment on in vivo DNA binding dates back to 1957 when 
Wheeler and Skipper measured the reaction of C-14-methyl-labelled nitrogen 
mustard with various DN As of · mice and rats [ 284]. In 1964 Brookes and 
Lawley showed that carcinogenicity for mouse skin of a num ber of polycyclic 
hydrocarbons correlates with covalent binding to skin DNA but not to skin pro-
tein [ 21]. Similar findings of a correlation of carcinogenic response to D NA 
binding but not to protein binding were reported for derivatives of 4-dimethyl-
aminoazobenzene [ 31], for N -hydroxy-2-acetylaminofluorene after different 
pretreatments [169] and for o-aminoazotoluene after chronic administration 
[140]. 
Since 1964, a variety of carcinogens have been studied for their effectiveness 
of binding to DNA in vivo and today, this Iist comprises of more than 80 
chemieals of many different classes of carcinogens (see sections 3.1 and 3.2). 
It includes a number of compounds which are barely detectable in the Ames 
test [172]: dimethylnitrosamine (Table 18), methylazoxymethanol (Table 17), 
4..dimethylaminoazobenzene (Table 16), 1,2-dimethylhydrazine (Table 17), 
safrol (Table 19), carbon tetrachloride (Table 13), urethane (Table 20) and 
ethionine (Table 20) [see Tables for refs.]. It therefore seems that DNA bind-
ing in intact mammalian organisms recognizes more carcinogens than any in 
vitro assay and that the result can, in addition, be interpreted in a quantitative 
way. 
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Unfortunately, the amount of chemical bound to DNA in vivo is very small 
and can hardly be detected by purely chemical means. Radioactive tracers 
(mostly C-14, H-3, or S-3 5) must therefore be used in such studies. This is the 
main limitation of the ·assay, restricting it to single compounds which are avail-
able in radiolabelled form commercially or by radiosynthesis. 
Most of the DNA-binding assays performed in the last 15 years aimed at the 
elucidation of the molecular basis of chemical carcinogenesis. The assay was 
not used for carcinogenicity testing, probably because its potential value was 
not clear with the small number of compounds investigated at that time. The 
results were also interpreted very· much like those of other short-term tests and 
the quantitative potency aspect of chemical carcinogens was established only 
within classes of related compounds. 
One attempt in this direction was undertaken in Brookes' laboratory [58]. 
They measured the binding of polycyclic hydrocarbons to DN A of mouse-
embryo cells in culture and established a Binding Index as DNA darnage divided 
by the dose incubated. The group of hydrocarbons with a high binding index 
consisted of potent carcinogens while the other group consisting of non-carci-
nogens and dibenz[a,h ]anthracene bad much lower values. 
This quantitative approach was not really expanded from the in vitro experi-
ments to the in vivo situation, although many studies have shown that the mea-
surement of a· binding of a chemical to DNA is related to the carcinogenic 
response only if' the experiment is carried out in vivo. 
With 4-dimethylaminoazobenzene, e.g., it was shown that binding to rat-liver 
DN A and tumor formation decreased after pretreatment with phenobarbital 
[53], while the ability of liver microsomes to form DNA-bound metabolites 
even increased after phenobarbital pretreatment [52]. Similar results were ob-
tained with aflatoxin B1 where pretreatment with phenobarbital reduces hepa-
tocarcinogenicity and DNA binding in liver in vivo [72], whereas in vitro 
results using microsomes from phenobarbital-pretreated rats show an efficient 
production of the ultimate carcinogen compared with control rats [70]. 
Despite this clearly higher relevance of in vivo studies, the cost of the radio-
active chemieals might require, in some cases, the study of an interaction with 
DN A und er in vitro conditions, where the local concentrations of chemical and 
DN A can be chosen much high er than is possible in an intact mammalian 
organism. 
We have, therefore, performed a number of in vitro experiments on the bind-
ing of a standard carcinogen, benzo[a]pyrene (BP), to DNA in order to see 
what sensitivity could be gained in the detection of a DNA binding in a model 
system [106]. Liver perfusion in situ, liver single cells, liver homogenate, liver 
microsomes incubated with DNA were used, as weil as fibroblasts from a rat 
granuloma pouch and two cell lines. It was found that the specific activities of 
the DNA differed by a factor of as much as 1600 between the in vivo experi-
ment (rat-liver DNA) and the microsomal incubation of DNA with BP. For-
tunately, the yield of DNA from the in vivo experiment is very high, so that the 
limit of detection of a binding in the two systems differs only by a factor of 
about 30. We consider this difference small if the relevance of the findings are 
compared. 
In addition, it was found that liver single cells gave rise to a DNA with a rela-
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tively high specific activity, and a Iimit of detection of a binding only 5 tim es 
greater than the system with the microsomes. Primary liver single cells could 
therefore provide a useful tool for the study of DNA binding if an in vivo 
experiment is too expensive but when a totallass of quantitative relevance, as 
with microsomal incubation, is to be avoided. 
2. 2. The in viuo "Co valent Binding Index": CBI 
· The promising quantitative· correlation of DN A binding in vivo with the car-
cinogenic response prompted us to expand Brookes' in vitro Binding Index to 
the in vivo situation, and examine a number of controversial compounds in 
intact mammalian organisms. 
For a comparison of different compounds, eventually studied in different 
laboratories and under various experimental conditions, the binding to DNA 
must be expressed per unit dose, such as 
darnage to DNA CBI=------
dose 
In agreement with earlier definitions of DNA damage, the following units were 
chosen: 
CB = micromole chemical bound per male nucleotides 1 
millimole chemical administered per kg animal 
These molar units allow a very rapid visualization of how many molecules are 
bound per milli an nucleotides after a theoretical dose of 1 mmole /kg. The 
actual dose or exposure of an animal or human to a carcinogen must always be 
accounted for, if the number of DNA adducts has to be estimated for a given 
dose. A multiplication of the CBI with the dose would be appropriate only in 
the case of linear dose-binding relationships. An estimation of the actual D NA 
darnage is a prerequisite for a risk assessment and it is clear that for two com-
pounds with similar CBI, e.g. benzene and ethinylestradiol (1. 7 and 1.5 for rat-
liver DNA resp.), it is very important to include all available knowledge on the 
actual daily dose for the humans exposed. 
The CBI unit chosen above is not very convenient for the actual experi-
ment because the amount of chemical is normally not represented in molar 
units but by its radioactivity (i.e. in Curies or dpm), and the amount of DNA is 
usually expressed in weight units, i.e. in milligrams. Since 1 mole nucleotides 
represents, on average, 309 g DNA, a CBI prime, CBI', could be defined as 
CBI' = dpm chemical bound per mg DNA 
dpm ~hemical administered per kg animal 
The experimental data can be processed easily with this formula, and then be 
converted to the molar units .. according to 
CBI' 
CBI = 3.24 . 10-9 
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A DNA-binding assay involves the following steps: (1) The administration of 
the radioactive chemical to the animal. (2) A waiting time of a few hours. ( 3) 
Isolation of DNA from relevant organs. ( 4) Liquid-scintillation counting of the 
DNA or DNA-carcinogen adducts isolated. 
It is obvious from the formula of the CBI' that the limit of detection of a 
binding is dependent on (1) The total radioactivity administered. (2) The 
amount of DNA in the scintillation vial. (3) The counting efficiency of the 
Iabel used. ( 4) The net radioactivity in the DNA-containing scintillation vial 
which can be considered significant. 
The · yield of DNA from an organ and the counting efficiency can be esti-
mated before the experiment is performed. The total radioactivity available is 
known as weil, and the Iowest significant radioactivity in a scintillation vial 
depends upon the purity of DNA and the rigorous exclusion of all contaminat-
ing radioactivities. In our hands, we can detect significantly as little as 2 cpm 
[158]. 
The limit of detection can now be calculated if the formula for the CBI' is 
rearranged to read 
significant cpm 
CBI, . . 1_ counting efficiency kg body weight mintma - al d d . . X 1 f f ( tot pm a mtntstered' yie d o DN A rom organ mg) 
For example, we have 100 J,LCurie C-14 Iabelied chemical available and 
would like to measure the binding to rat-liver DNA. Per kg rat there are about 
40 g liver with a yield, in our hands, of about 60 mg DNA. If we enter the 
above formula with these data, taking 2 cpm as a significant radioactivity and a 
counting efficiency of 80%, the equation is now 
CBI'min (Iimit of detection) = 2_22
2
:
5
108 X 6
1
0 = 1.9 · 10-
10 or CBI min = 0.06 
It can be seen from these equations that the size of the animal does not have a 
direct influence on the Iimit of detection of DNA bindingifit is approximated 
that the weight of an organ (and of its amount of DNA) is proportional to the 
total weight of the animal. This theory has its Iimitation on the experimental 
side because it should be impossible to measure the radioactivity on the total 
amount of an elephant's liver DNA in one scintillation vial. 
2.3. Choice of experimental conditions for the measurement of a CBI 
The suggestions made in the next sections have been followed in our own 
recent experiments. The CBI calculated from the Iiterature data and compiled 
in the Table~ 13-20 are based on experiments which do not always conform to 
these standards. 
2.3.1. Position of the radioactiue Iabel 
Fora DNA-binding assay in vivo a radiolabel is a prerequisite except for the 
very rare carcinogens with extremely high Binding Indices, like some N -nitroso-
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compounds (Table 18) or aflatoxin B1 [131]. Since the radioactivity on the 
DNA is the measure for bound chemical it is obvious that a binding can only be 
detected if the portion of the compound which is bound to the DNA still 
carries the label. It is therefore important to evaluate the pharmacokinetic data 
available in order to assess the probability for a certain part of the molecule to 
become an alkylating moiety [ 7 5]. Since a great deal is already known about the 
metabolic activation of all classes of carcinogens, it is in most cases possible to 
predict whether a given radioactive Iabel will stay in the binding portion of the 
molecule or not. 
This fact that only a part of the molecule might be bound to the DNA was, 
in some cases, used for the elucidation of the metaboiic steps and eventual 
cleavage of the molecule in the generation of the ultimate carcinogen. With 
4-dimethylaminoazobenzene, tritiated in the amino ring and C-14 labelled in 
the prime ring, it was shown that both benzene rings are bound tagether to 
DNA [55]. Such mixed-labe! studies with urethane suggested that only the 
ethyl group is bound to rat nucleic acid:s [213], whereas in mice, the carboxyl 
carbon also seems to beattached [18,143].Additionalexperimentswithethoxy-
0-18 Iabel in mice did not, however, give rise to an 0-18 isotope enrichment on 
the DNA [208]. Therefore, there is still no agreement about the alkylating 
moiety of urethane. Such problems can arise from compounds with barely 
known or complicated patterns of metabolites, especially where a relatively 
small fraction of the total nurober of metabolites is responsible for all DNA 
binding. 
Another point which must be considered is that mostchemieals have a num-
ber of different routes of oxidation and degradation, some of which might Iead 
to the loss of the Iabel which could then be incorporated biosynthetically into 
DNA. Most commonly, with tritiated compounds Iabelied at a number of posi-
tions some tritium is always lost, either by exchange or by oxidative processes. 
The tritiated water formed can then be incorporated into the nucleotides. This 
is most easily done via the reduction of ribose to 2-deoxyribose where a 
proton, or in this case a tritium ion from the water pool replaces the 2-hydroxy 
group. 
With tritiated compounds there is therefore always the danger that the Iabel 
is incorporated into DNA in a stable form and cannot be distinguished· from 
covalently bound chemical without degradation of the DNA. Appropriate con· 
trol experiments are described in section 2.4.3. 
As opposed to this drawback of general tritium labeHing these compounds 
have the advantage that the DNA-bound molecule still carries most, if not all 
(benzo [ a] pyrene [ 196]) of the Iabel so that a binding cannot be missed. 
2.3.2. Dose and dose schedule 
In general pharmacology it is an accepted fact that the kinetics of absorp-
tion, distribution, and metabolism are greatly influeilced by the dose. From a 
small dose of vinyl chloride, for example, almost 100% is metabolized. With 
higher doses, however, the amount metabolized does not increase proportion-
ally [ 89] , but an increasing fraction is expired [ 81] . This happens bec~use of a 
saturation of the oxidation pathway which is also responsible for the activation 
of vinyl chloride to a chemically reactive metabolite [10]. In this critical range, 
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the doubling of the dose does not, therefore, Iead to the doubling of the forma-
tion of reactive metabolites so that covalent binding to macromolecules and 
carcinogenic response does not increase linearly with the dose either 0 
Such fundamental theories on saturation processes seem to be forgotten 
when long-term bioassays are planned and interpreted. These assays are nor-
mally performed with extremely high oral dosage. This is necessary in order to 
get a significant yield of tumors with a small nurober of animals. The results 
might :tJe misleading because an extrapolation of such a finding to lower doses 
cannot be based upon any mathematical model without knowledge of the dase-
rlependent profile of metabolites. In addition, it is known that the enzymatic 
activity induced by a high dose of a polycyclic hydrocarbon can alter the rela-
tive amounts of the different metabolites and, with this, alter the amount of 
DNA adducts formed [159,277]. 
For a DNA-binding assay it would therefore be appropriate to use a dose 
which is in the same order of magnitude asthat of human exposure. In most 
cases, however, this will not be feasible because the specific radioactivity is not 
high enough and a satisfactory Iimit of detection could not be reached with the 
total radioactivity administered with a low dose. In any event, it is in most 
cases unwise to dilute the radioactive sample with inactive chemical, and the 
dose should be so Iow that the binding to DNA can just significantly be mea-
sured. 
Obviously, the determination of a dose-DNA-binding relationship would 
answer the question of a non-linearity and this has indeed been donein a nuro-
ber of cases. The results will be discussed in section 5.4.1. 
Exposur~· ()f humans to environmental carcinogens lasts a whole lifetime. It 
would thert-.. Jre be interesting to pretreat the animals with the compound to be 
tested 0 This can be very costly if radioactive material is used for the full period 
of treatment. The rare experiments where this has been done are discussed in 
section 5.4.2. The results are interesting with respect to the mechanism of 
carcinogenic action but they do not improve the prediction of the carcinogenic 
potency of a chemical because of the high cumulative dose obtained with such 
schedules. 
2.3.3. Solvent and route of administration 
The solvent used for the administration should be chemically and pharmacol-
ogically inert. An aqueous solution is appropriate for water-soluble compounds. 
For lipophilic chemicals, the carrier should not interfere with the bioavail-
ability of the compound tested and it should be processed by different metab-
olic routes and enzymes or should be completely undegradable. This could 
therefore be a methylcellulose solution, a solution in dilute alcohol or a solu-
tion in oil. Dimethylsulphoxide should be avoided since it has been shown to 
form macromolecular complexes with many types of chemieals [105] and to 
protect rat-liver DNA from strand breaks by dimethylnitrosamine but not by 
methylnitrosourea [252] probably by interfering with the oxidative demethyla-
tion reaction. 
The raute of administration of volatile compounds is preferably by inhala-
tion. Inhalation experiments are often complicated by the fact that a part of 
the dose can be lost by expiration after stopping the exposure. It is therefore 
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difficult to determine the exact dose administered and calculate a CBI. We have 
developed a closed inhalation chamber (Fig. 4) [156] where a smalllaboratory 
animal can be kept in the same atmosphere for up to 24 h. The only gas 
exchange is the adsorption of the expired carbon dioxide on soda lime and an 
equimolar replacement with oxygen. The disappearance of the chemical investi-
gated from the atmosphere can be followed by air sampling and gas-chromatog-
raphic analysis. Such a system allows for a complete metabolism of a given 
amount of chemical and was used in the study of the binding properties of ben-
zene [157] and· toluene. A similar all-glass system without automatic oxygen 
supply was described before and used for the study of vinyl chloride (8]. 
If, for any reason, an inhalation experiment cannot be performed, intra-
venous (i.v.) or subcutaneous (s.c.) administration is probably the most similar 
raute if local effects on the respiratory system are not to be assessed. As a 
vehicle for i.v. injections of lipophilic compounds we have successfully taken 
serum of syngeneic animals which has reasonable solubilizing properties thanks 
to lipophilic protein binding sites [ 277]. 
Oral intake is a very common raute of exposure to environmental carci-
nogens. One might therefore tend to think that this is also the appropriate 
route of administration in a binding assay with Iabaratory rodents. One should, 
in this connection, not forget that eating habits, intestinal anatomy and pH, 
intestinal flora and basal metabolism are different in rodents and humans. 
These differences could have a substantial influence on intestinal metabolism, 
bioavailability and absorption and, as a consequence, also on DNA binding. 
The pig is an animal species which is very close to the human with respect to 
such dietary functions. We were interested to compare DNA binding in this spe-
cies with that in the rat and have performed an assay with orally administered 
aflatoxin B1• The CBI for liver was about 5 times higher in the pig than in 
the rat (Table 19) but it is possible that other parameters than the intestinal 
functions have contributed to this difference (see chapters 5 and 6). 
Fig. 4. Schematic view of a Closed inhalation system. A .. regular glass desiccator as chamber. B. soda lime 
for the adsorption of carbon dioxide. C, U-type manometer. filled with water. D, oxygen lnlet. E, water 
bottle (or thermometer). F, holder for a rubber septum for air sampllng with needle and syringe. G. 
oxygen supply system. With tbis arrangement of gas washing bottles a slight and constant underpressure· 
(~P). given by the dlfference in the water Ievels, can be maintained in the chamber. This allows for a con-
tinuous control whether the chamber is air-tight. Only when tbe pressure decreases below that value does 
oxygen bubble tbrough the left bottle into the chamber and restores the desired underpressure. H. glass 
U-tube with teflon valves for trapping volatile radiochemieals in liquid nltrogen from break-seal ampoules 
wlth subsequent transfer into the chamber in the oxygen flow. 
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A number of compounds have been tested for DNA binding afterdifferent 
routes of administration. These examples are easily found in Tables 13-20 
while here it is sufficient to .summarize that there is no great difference in the 
Binding Index for liver DNA after intravenous, intraperitoneal or subcutaneous 
injection. An oral administration reduces the binding index by a factor of 5-10 
with the polycyclic aromatic hydrocarbons, but has only a slight reducing influ~ 
ence on N-nitroso compounds or aflatoxin B1 • For organs other than the liver, 
this influence might be different, especially if one takes into account the strong 
local effects of some carcinogens that do not need metabolic activation, or 
first-pass effects for carcinogens which are rapidly metabolized in the liver after 
oral or intraperitoneal administration. 
The intraperitoneal administration is somewhat artificial, but it is easy 
experimentally and it mirnies an oral administration because most of the blood 
vessels of the peritoneal cavity empty into the portal vein. A DN A-binding 
assay for liver would therefore yield a theoretical binding potency expected for 
complete absorption of a chemical unchanged by gastro-intestinal processes. 
2.3.4. Time betweeri administration and sacri{ice 
The amount of chemical bound to DNA rises steeply in the frrst minutes and 
hours, Ievels-off, and decreases slowly thereafter according to the chemical 
stability of the adduct, enzymatic excision of the damaged DNA, and cell 
death. The binding should optimally be measured at its maximum Ievel. This 
can be in an hour or less after intravenous administration of a low dose of an 
alkylating agent which does not need enzymatic activation (methylnitrosourea) 
[201]. It can, on the other band, take 20 h to reach the maximallevel of DNA 
binding after intraperitoneal administration in oil of a very high dose of a lipo-
philic compounds which needs enzymatic activation (2-methyl~4-dimethyl­
aminoazobenzene, 150 mg/kg, 10 ml oilfkg) [279]. The time needed to reach 
maximum binding is therefore dependent on the time that it takes for the 
chemical to diffuse or be transported from the site of administration into the 
target organ, to the activating enzymes and finally to the DNA. 3~ h seem 
reasonable for intravenous, 6-12 h for intraperitoneal or oral administrations 
of small doses of slightly water-soluble chemicals. The shorter this period of 
time, the smaller is the extent of incorporation of radioactive fragments by bio-
synthetic routes (section 2.4.3). 
A time dependence of the binding could of course be determined. This has 
indeed been done with many carcinogens (see Tables 13-20) in order to gain 
some insight into the DNA-repair processes and the results are discussed in sec-
tion 4.3.2. To summarize at this point, it was shown that the persistence of 
DNA-bound chemical reflects a certain refractoriness to DNA repair which is an 
important modulator of the carcinogenic consequences of DNA binding. 
It would therefore be very valuable to measure DNA binding at two points 
in time, the first around the maximum Ievel of binding as discussed above, and 
the second at about one week after the administration. For the later point in 
time it will, however, be necessary in many cases, to degrade the DNA and 
make sure that the radioactivity measured is really due to an adduct and is not 
a result of biosynthetic incorporation of the labe!. In addition, the following 
two points must be considered: (i) The chemical stability of the adduct: for 
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example, alkylation of guanine at nitrogen-7, Ieads to a positive charg~ which 
renders the nucleoside relatively unstable. A depurination is the obvious con-
sequence with a loss of the base. This reaction occurs in vivo as weil as during 
the isolation of DNA and might simulate arepair activity. (ii) Cell death might 
occur when the alkylation darnage does not permit the survival of the cell. A 
degradation of the cellular constituents of such dead cells mirnies a time-depen-
dent removal of DNA-bound Iabel which at first sight cannot be separated from 
real repair processes and might also show non-linear repair activity with the 
dose of the carcinogen. If enzymatic repair processes are to be followed, it will 
therefore be necessary to compare the rates of removal of various DNA-bound 
adducts. 
2.3.5. Isolation of DNA. Liquid-scintillation counting 
Since the Iimit of detection of a binding is directly related to the yield of 
DNA it is obvious that large or DNA-rich organs are most attractive. This is 
one reason why Iiver is examined in most cases, the second reason being that 
liver contains all the enzymes necessary for the activation of all known car-
cinogens. It is therefore not surprising that the very early studies on DNA bind-
ing were done with hepatocarcinogens and liver DNA. Liver DNA was 
examined also with compounds that do not give rise to liver tumors and it was 
surprising to see that CBI for liver give, nevertheless, quantitative results on the 
carcinogenic potency of compounds that induce tumors in argans other than 
the liver (see section 4.2). 
Within a specific organ there are various types of cells that can differ sub-
stantially from each other with respect to their drug-metabolizing capacities. 
Thus, if a CBI for testis is determined, this represents an average and it is 
dangeraus to stress too much the quantitative aspect of a DN A binding assay 
for argans with a large nurober of different cell types. 
Several methods are available for the isolation of DNA. We use, after a 
phenol :chloroform extraction, a hydroxyapatite adsorption chromatography 
which can be performed with large amounts of DNA but does not allow the· 
highest yield. After dialysis and precipitation with ethanol the D NA is redis· 
solved in phosphate buffer and the radioactivity is counted after the addition 
of scintillation cocktail [277]. 
It was shown in the original report by Markov and Ivanov [166] that this 
procedure yields a DNA with maximum contaminations of 1% RNA and less 
than 1% protein. The detennination of this low level of protein was performed 
with a radioactive precursor, 35S·methionine, and a determination of the spe-
cific activity ~f chromatin protein, a probable DNA contaminant. With this 
experimental set-up we determined 0.5% protein on the DNA isolated from rat 
liver. An additional, but less sensitive criterion for protein contaminations is 
the UV absorbance ratio A260 nm/A230 nm. Nucleic acids have a maximum 
around 260 nm and a minimum around 230 nm, protein has a minimum near 
255 nm and a strong side absorption from the amide bond at 230 nm. All our 
DNA samples exhibit an absorbance ratio of better than 2.3, which is as good 
as those published in the original report [166]. 
In order for this low amount of protein to have a marked influence on the 
total radioactivity of the DNA sample, the Specific activity of the protein 
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would have to be orders of magnitude above · that of the DN A. A difference 
of a factor of two hundred would result in equal contributions of the DNA 
and the 0.5% protein to the. total radioactivity measured. This would then be 
responsible for an error of a factor of two for the Covalent Binding Index, CBI. 
It will be seen in chapter 4 that even such a remarkable error would not have a 
great influence on the classification of the chemieals into the classes of strong, 
moderate, or weak carcinogens because the total range of CBI covers more than 
6. orders of magnitude. 
Simultaneaus determination of protein and DN A binding has been reported 
for many carcinogens, and factors of up to one hundred have been shown [37, 
97 ,280]. In most cases, however, the specific activity of cytoplasmic protein is 
less than 10 times higher than that of DNA. This range was determined with 
mustards [ 23], polycyclic aromatic hydrocarbons [ 21], azo derivatives of aro-
matic amines [31,140,141], and a nurober of N-nitroso compounds [149], i.e., 
with representatives of many possible classes of carcinogens. On the other 
hand, with aflatoxin B~t rat-liver DNA reaches a higher specific activity than 
cytoplasmic protein [71,265]. In addition, it is to be noted that in most cases 
these specific activities were determined with phenol-extractable protein which 
is not a likely contaminant of DNA. The nuclear proteins isolated in one of the 
sturlies had only about a third of the specific activity of the · cytoplasmic pro-
tein [97]. 
A contamination of the DNA with RNA is not critical either, because the 
nucleophilic centers of these macromolecules are almost identical and only the 
local concentration of ultimate carcinogen determines the ratio of DNA-
versus RNA--adduct formation. The specific activities of DNA and RNA always 
ranged within one order of magnitude so that a 1% contamination of DN A with 
RNA cannot distort the binding data by more than 10%. 
Probably a more important problern with the purification of the DNA is the 
avoidance of any radioactive contamination. It should be bome in mind that a 
DN A-binding experiment starts with milli Curie amounts of radioactivity and 
only a few cpm an the DNA have tobe measured in the end. In our laboratory, 
we therefore have a strict Separation of glassware, disposable pipettes, siphons, 
scintillation cocktails, refrigerators and freezers used for the isolation steps 
after the hydroxyapatite column. Each person involved in the isolation of DNA 
has his personal glassware of these critical steps and only fresh, precounted, low 
background glass scintillation vials should be used. 
2.4. Control experiments 
The control experiments discussed in this section are necessary if the DNA 
adduc~ are not positively identified by chromatography of the nucleosides and 
adducts after enzymatic breakdown of the DNA [126,207, and refs. therein]. 
Such a proof of adduct formationwill always be required if the biosynthetic 
incorporation of radioactivity into nonnal nucleosides cannot be properly 
taken into account (section 2.4.3). The further handling and processing of 
DN A for these determinations obviously im pau-s the Iimit of detection of a 
binding because of the inevitable additionallass of material and, more severely, 
because some adducts are resistant to complete hydrolysis. This was shown 
with a number of polycyclic hydrocarbons [196,207], _where a considerable 
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fraction of the reaction products with DNA did not show up with the adduct 
peaks of a Sephadex LH20 chromatogram but was heading the unmodified 
nucleosides. 
2.4.1. Background radioactivity 
Background radioactivity is always detennined from a DN A sample isolated 
from a control animal which is administered unlabelled chemical. The gross 
radioactivity of these samples can be held within less than 1 cpm as one stan-
dard deviation if the precautions mentioned in the last paragraph are observed. 
2.4.2. Intercalation. Tritium exchange 
The measurement of radioactivity on the DNA sample does not teil us right 
away whether the compound is bound covalently or whether it is merely inter-
calated and bound physico-chemically and was not removed from the DNA 
during the isolation procedure. In order to determine ~his non-enzymatic bind-
ing, we regularly incubate radio-labelled chemical with ithe total homogenate of 
a control liver in the denaturing medium used as the first step for the isolation 
of DNA. It is assumed that undersuch conditions (8 ~ urea, 1% sodium dode-
cyl sulphate, 10 mM EDTA in sodium phosphate buffek) a metabolic activation 
of the test compound to a reactive derivative does not occur. This incubation, 
of course, cannot be done with directly alkylating compounds. The incubation 
must be carried out in the dark and under nitrogen in orderte exclude photo-
oxidative reactions which might also lead to covalently bound chemical. After 
0.5 h of gentle shaking at 37° C, DNA is isolated from that liver homogenate by 
the regular purification procedure, and the radioactivity on that DN A teils us 
whether our isolation method has freed the DNA from intercalated chemical, 
and whether exchanged tritium atoms have also been removed. 
So far, the radioactivity associated with DNA after this incubation has never 
exceeded 0.~% ofthat from the actual experiment if the specific activity of the 
liver homogenate of the control experiment was equal to that of the liver of the . 
treated animals at the time of sacrifice. This maximum value was found with 
7 ,12-dimethylbenz[ a] anthracene under 'conditions where a photo-oxidation 
reaction could weil have taken place (20 h under air and normal light). It is 
known from this and related compounds (benzo[a]pyrene) that non-enzymatic 
covalent binding does take place [ 83]. 
2.4.3. Biosynthetic incorporation of radioactiuity 
As was mentioned in section 2.3.1, biosynthetic incorporation of radioactiv-
ity into DNA can occur if a spontaneaus or enzymatic degradation of the 
labelled compound releases the radioactive labelas a small molecule. 
Tritiated compounds almost inevitably lead to the formati.on of tritiated 
water of which a tritium ion can quite efficiently be incorporated into newly 
synthesized DNA. In order to account for this incorporation the specific activ-
ity of the body water must be known and a comparison with control experi-
ments with tritiated water will provide an estimate on that part of the radioac-
tivity of DNA that is due to tritiated water. 
Such control experiments were performed with oral doses of about 10 mCi 
tritiated water per kg rat, and liver DNA was isolated after 12, 24 and 48 h. 
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Fig. 5 shows the results for adolescent and adult animals. The incorporation of 
radioactivity into DNA increased linearly with time, thus indicating a biosyn-
thetic mode of incorporation.and reflecting the fact that the half-life of tritium 
in the tritiated water pool of the animal is larger than our period of observa-
tion. No difference is seen between the age groups which means that the rate of 
DNA synthesis in liver does not differ significantly. The low CBI values ob-
tained from these experiments show that this incorporation is not very critica}. 
for liver DNA (about 21 dpm/mg, 12 h after an oral dose of 10 mCi/kg). The 
tritium radioactivity measured on the DN A of these control experiments repre-
sents stable incorporation into non-exchangeable positions as can be deduced 
from the control incubation described in the legend to Fig. 5. 
lf the CBI for tritiated water given in Fig. 5 are taken as the basis for a cal-
culation, one important aspect should not be overlooked: the fact that an oral 
dose of tritiated water yields a uniform distribution of radioactivity in the total 
body water whereas an enzymatic formation of tritiated water occurs intracel-
lularly only and gives rise to higher Iocal specific activities initially, with a prob-
ably higher chance of an incorporation of tritium into DNA. This was indeed 
found with a comparison of the Binding Indices of tritiated versus C·l4labelled 
benzene [157]. The CBI for liver DNA from C-14 Iabelied benzene amounted to 
1.7 (Table 14), whereas the tritiated compound gave rise to an apparent CBI of 
2.4, probably because of the additional radioactivity incorporated from the tri-
tiated water formed. 
The specific activity of tritiated body water was determined from a s~all 
diluted aliquot of the urine collected at the time of sacrifice. This turned out to 
be about 20 ~-tCi/ml urine. Under the reasonable assumption that the specific 
activity of urine is equal to that of the total body water, this specific activity 
corresponds to a dose of about 16 mCi/kg rat which would have contributed 
about 26 dpm/mg liver DNA according to our control experiments. In the 
CBI 
I 
3 
2 
1 
Fig. 5. Time course of the incorporation of tritium from tritiated water (HTO) into rat-liver DNA. Young 
(O, 108-124 g) and adult (•, 282-307 g) male rats (SIV-50, Sprague-Dawley-derived) were glven by 
gavage about 10 mCi HTO Per kg body weigbt. At the time indicated, DNA from liver was isolated and 
counted by liquid scintillation (20-80 dpmfmg). The incorporation is sbown as a fraction of the dose, on 
the left hand si.de in CBI units of micromole tritium/mole nucleotides per mmole HTO/kg body weight, on 
the rigbt hand scale in CBI' units of dpm/mg DNA per dpm/kg (see section 2.2 for more information on 
these units). CBI mean and standard deviation from the 4 animals at each time point are 0.29 ± 0.06 (12 
h), 0.56 ± 0.07 (24 b), 0.97 ± 0.07 (48 h). Control experiment (section 2.4.3), incubation of 50 ml dena-
tured homogenate of 6.5 g liver with 72 iJCi HTO for 12 h at 37°C did not Iead to a measurable radioac-
tivity on the DNA isolated (2 cpm as Iimit of detection). 
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actual experiment, however, the difference between the tritium and C-14 
experiment was 280 dpm/mg DNA. We therefore believe that the intracellular 
formation of tritiated water gives rise to an incorporation into liver DN A about 
10 tim es high er than if the radioactivity is distributed uniformly from the 
· beginning. 
A biosynthetic incorporation of radioactivity into DNA has tobe considered 
also with C-14 labelled compounds. The effect is most pronounced with com-
pounds where small metabolites can carry the radioactive Iabel, as with methyl-
ating and ethylating agents. With the pesticide dichlorvos, för instance, all 
radioactivity found in the DN A of rats treated with methyl-labelled chemical 
was found to be incorporated biosynthetically and not a result of direct meth-
ylation [289]. This finding does not, of course, exclude a methylating potential 
of dichlorvos in vitro [137], but it shows that, at the given dose, the pesticide 
did not reach the mammalian DNA as an alkylating agent. 
An incorporation of such small [C-14]- or tritium-containing fragments into 
nucleic acid bases and sugars is very well known since the elucidation of the 
biosynthesis of nucleic acids [ 30]. However, only incomplete experimental 
evidence is available on its contribution to the total radioactivity of the DNA 
after the administration of alkylating agents. This is due to the fact that meth-
ylated or ethylated DNA is normally directly degraded by acid hydrolysis to 
the bases which are then chromatographed [ 138] . An incorporation into the 
sugars is only seldom accounted for, but the available evidence suggests that 
this incorporation is not critical [ 194]. The biosyn thetic incorporation into the 
bases can, however, represent up to 20% of the total radioactivity in a short-
tenn experiment with a typical methylating carcinogen [67,120,194]. The 
same order of magnitude can be estimated from the apparent CBI of [C-14]-
bicarbonate or 1-[C-14]ethanol for mause-liver DNA, 24 h after i.p. injection 
[ 18]: 0.3, and 4.6, resp. These numbers are small compared with the CBI for 
methylating carcinogens so that the measurement of a total radioactivity is still 
a valuable indicator for the potency of moderate or strong carcinogens. 
For ,·other classes of carcinogens, a potential release of small radioactive frag-
ments capable of entering biosynthetic pools of nucleic acid precursors, can 
only be excluded on the basis of data on metabolism. It is, however, extremely 
unlikely tha~, for example, a C-14 of an aromatic hydrocarbon or of a ring-
labelled aflatoxin could become a significant biosynthetic contaminant in a 
DNA-binding experiment. 
3. Lists of chemieals that have been tested for covalent binding to biological 
macromolecules under various experimental conditions 
3.1. Introduction 
More than 150 compounds have so far been tested for covalent binding to 
biological macromolecules. The relevance of the experiments varies with the 
type of macromolecule and experimental system chosen. As was outlined 
before, DNA binding in vivo is most valuable whereas protein binding in vitro 
can only be used very qualitatively. The compounds studied so far are listed in 
Tables 1-12 according to chemical characteristics relevant for their binding 
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TABLE 1 
LIST OF CHEMICALS THAT HAVE.BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
SULPHONATES, SULPHATES, EPOXIDES. LACTONES, AZIRIDJNES, EPJSULPHIDES 
Listed according to chemical characteristics relevant for the binding activity with a cross-reference to 
drugs (D) and pesticides/environmental pollutants (P). 
The number behind each compound denotes the type of experiment that has been performed on covalent 
binding to biological macromolecules. Only the lowest number is given even if other types of experiments 
have also been performed. 
Refs. for compounds of class 1 and 2 are given in the corresponding Tables 13-20 and 21-25, resp. 
For compounds of class 3-6, only recent reference is given. 
1 In vivo to DNA, calculation of a Covalent Binding Index, CBI. 
2 In vivo to DNA, calculation of a CBI was not possible. 
3 In vivo to protein. 
4 In vitro to nucleic acids. 
5 In vitro to protein. 
6 Tbe test for a binding to DNA was negative (various Iimits of detection!) 
Methyl methanesulphonate 
Ethyl methanesulphonate 
Myleran (=Busulfan) 
Dimethylsulphate 
1,2 ,3 ,4-Diepoxybutane 
1,2-Epoxybutane 
1,2 ,3 ,4·Diepoxycyclohexane 
ß-Propiolactone 
D 
Triethylenemelamine ( TEM) D 
Triaziquone D 
Mitomycin C D 
3,4: -Epithio bu tyronitrile 
1 
1 
1 
1 
2 
6 Paul 
6 Pau) 
2 
1 
4 Harbers 
4 Szybalski 
Tomasz 
1 
[199] 
[199] 
[86] 
[267] 
[272] 
activity, and each chemical is given a number to denote the type of interaction 
studied. 
All chemical classes of carcinogens are represented in this Iist: Tables 1 and 2 
comprise of the chemieals which do not need metabolic activation ( except 
cyclophosphamide): The directly alkylating sulphonates, sulphates, epoxides, 
TABLE 2 
LIST OF CHEMlCALS THAT HAVE BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
MUSTAROS (ß.CHLOROETHYLENE-DERIV ATIVES) 
See Table 1 for legend. 
Nitrogen mustard 
Sulphur mustard 
Hemisulphur mustard 
Aniline mustard 
/1-Napbthylamine mustard 
Cyclophosphamide 
ChlorambucU 
D 
D 
1 
2 
1 
2 
2 
1 
2 
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TADLE 3 
LIST OF CHEMICALS TRAT HAVE BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
HALOqENATED COMPOUNDS (MUSTARDS: SEE TADLE 2) 
See Ta ble 1 for legend. 
Chlorofonn 3 nett [100] 
Fluoro·trichlorometbane 5 Uehleke [276] 
Bromo-trichloromethane 5 Sipes [246] 
Carbon tetrachloride 1 
Vinyl chloride 1 
Vinyl bromide 4 Ottenwaelder [198] 
Trichloroethylene 3 Uehleke [276] 
4 Baneriee [4) 
1 ,2-Dibromoethane 1 
Bromobenzene 6 Jollow [114] 
Iodoacetic acid 2 
3-Chloropropionic acid 2 
3-Iodopropionic acid 2 
Halothane D 3 Hempel [93] 
Rao [216] 
Hexachlorophene D 5 Miller III [179) 
Chloramphenicol D 3 Bonanomi [11] 
Thiamphenicol D 6 Krishna [130] 
Dichlorvos p 6 Wooder [289] 
Dieldrin p 5 Jakubowski [108] 
TCDD p 6 Nelson [188] 
Polychlorinated biphenyls p 6 Shimada [241] 
TADLE 4 
LIST OF CHEMICALS THAT HAVE BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
AROMATIC HYDROCARBONS 
See Table 1 for legend. 
Benzene 
Toluene 
Naphthalene 
Anthracene 
Benz(a] anthracene 
Dibenz[a,c] anthracene 
Dibenz[a,h] anthracene 
Benzo [a 1 pyrene 
Benzo[e] pyrene 
trans..Stilbene 
Styrene 
7-Methylbenz[a] anthracene 
7 ,12-Dimethylbenz[a) antbracene 
3-Metbylcbolanthrene 
16,16-Dibydro-11-metbylcyclopenta[a] phenanthren-1 7·one 
1 
1 
3,6 Brookes [21] 
2 
1 
2 at Iimit of detection 
2 
1 
6 Brookes [24] 
3 Docks [66] 
3 Savolainen [229] 
4 Newbold [191] 
1 
1 
4 Coombs [39] 
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TABLE 5 
LIST OF CHEMICALS THAT HAVE BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
AMINOFLUORENE- AND AMJNOPHENANTHRENE-DERIVATIVES 
See Table 1 for legend. 
2-Aminofluorene 
2-Acetylaminofluorene 
1·H ydrox y-2-acetylamino fluorene 
N-Hydroxy-2-acetylaminofluorene 
N -Acetoxy -2-acetylaminofluorene 
N-(Glucuronyl-10)-2-acetylaminofluorene 
N-Acetoxy-2-acetylaminophenanthrene 
N -Sulfonoxy -2-acetylaminophenanthrene 
N-(0-Glucuronyl)-2-acetylaminophenanthrene 
TABLE 6 
1 
1 
1 
1 
1 
1 
4 
4 
4 
Lang 
Scribner 
lrving 
[133] 
[235] 
[104] 
LIST OF CHEMICALS THAT HA VE BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
AZO-DERIVATIVES OF AROMATIC AMINES 
See Table 1 for legend. 
N-Methyl-4-aminoazobenzene 
4-Dimethylaminoazobenzene 
2-Methyl-4-dimeth ylaminoazo benzene 
3' -Methyl-4-dimethylaminoazobenzene 
3' -Trifluoromethyl-4-dirnethylaminoazobenzene 
o-Aminoazotoluene 
p-Aminoazobenzene 
TABLE 7 
1 
1 
1 
1 
1 
1 
1 
LIST OF CHEMICALS THAT HAVE BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
OTHER AROMATIC AMINES 
See Table 1 for legend. 
Aniline 1 
2,4-Diaminotoluene 3 Dybing [59] 
2,4-Diaminoanisole 3 Dybing [59] 
3-Chloro-4-methylaniline 3 Giri [76] 
2-Naphthylamine 1 
N-Hydroxy-1-naphthylamine 4 Kadlubar [116] 
N-Hydroxy-2-naphthylamine 4 Kadlubar (115) 
N-Hydroxy-4-aminobiphenyl 4 Kadlubar [115] 
N-Hydroxy-4-acetylaminobiphenyl 1 
N -Hydroxy-4-acetylamino-4 '·fluorobiphen yl 1 
N -Acetoxy-4-acetylaminobiphenyl 4 Lang (134] 
trans-Dirnethylaminostilbene 1 
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TABLE 8 
LIST OF CHEMICALS THAT HAVE BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
ALIPHATJC AMINES, HYDRAZINES, AZOXY- AND NITRO-DERIVATIVES, TRIAZENES 
See Table 1 for legend. 
Dopa 
Doparnine 
6-Hydroxy-doparnine 
5,6-Dihydroxytryptarnine 
5, 7 -Dihydroxytryptamine 
N orepinephrine 
Imipramine 
Isoproterenol 
Tripelennarnine 
1,2-Dimethylhydrazine 
Acetylhydrazine (from isoniazid D) 
Isopropylhydrazine (from iproniazid D) 
Methylazoxymethanol acetate (from cycasin) 
Cycasin 
Methylphenyltriazene 
Dimethylphenyltriazene 
Dacarbazine 
4-Nitroquinoline-1-oxide 
4-Hydroxyaminoquinoline-1-oxide 
1-Nitro-9-(3'-dimethyl-n-propylarnino)acridine 
TABLE 9 
D 
D 
D 
D 
D 
D 
D 
5 
5 
5 
5 
5 
5 
3 
3 
3 
1 
3 
3 
1 
2 
1 
1 
2 
2 
2 
2 
Sc heulen 
Sc heulen 
Rotman 
Rotman 
Rotman 
Rotman 
Rotman 
Kappus 
Remmer 
Rao 
Nelson 
Nelson 
[231] 
[231] 
[226] 
[226] 
[226] 
[226] 
[226] 
[118] 
[218] 
[215] 
[187] 
[187] 
LIST OF CHEMICALS THAT HAVE BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
N-NITROSO·DERIV ATIVES 
See Table 1 for legend. 
Dirnethylnitrosamine 
Diethylnitrosamine 
Methylnitroseurea 
Ethylnitrosourea 
Methylnitroseurethane 
Methylnitronitrosoguanidine 
Nitrosohexamethyleneimine 
Nitrosomorpholine 
M eth ylni trosoaniline 
Methylnitrosocyclohexylamine 
Nitrosoazetidine 
Nitrosopyrrolidine 
Nitrosepiperidine 
Dinitrosopiperazine 
Nitrosotripelennamine 
Nitrosocarbaryl 
1 
1 
1 
1 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
3 Rao [215] 
4 Regan [217] 
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TABLElO 
LIST OF CHEMICALS THAT HAVE BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
NATURALLY OCCURRING COMPOUNDS 
See Table 1 for legend. 
Afiatoxin B 1 1 
Aflatoxin 82 1 
Aflatoxin G 1 1 
Aflatoxin M 1 1 
1 '-Hydroxysafrole 1 
Retronecine-7 .9-bis-N -ethy lcarbama te 3 Mattocks [171) 
Synthanecine A bis-N-ethylcarbamate 3 Mattocks [171] 
Xanthotoxin 4 Kittler (119] 
Angelicin 4 Kittler [119] 
Phorbol-12,13-didecanoate 3 Helmes [92] 
Phorbol-12,13-dibenzoate 3 Helmes [92) 
Cholestcrol 4 Zachariah [293) 
Cholic acid 4 Zachariah [293) 
Deoxycholic acid 4 Zachariah [293] 
Iactones, aziridines, and episulphides (= thiiranes) (Table 1), and the mustards 
(ß-chloroethylene derivatives, Table 2). 
All the other chemieals require metabolic activation with only very few 
exceptions and are grouped as follows: halogenated compounds, except mus-
tards (Table 3). aromatic hydrocarbons (Table 4), the long Iist of aromatic 
amines which have been subdivided for practical purposes into aminofluorene 
and aminophenanthrene derivatives (Table 5 ), azo-derivatives (Table 6) and 
other aromatic a~ines (T.able 7). Table 8 includes the rest of the nitrogen-con-
TABLE11 
LIST OF CHEMICALS THAT HAVE BEEN TESTED FOR COVALENT BINDING TO BIOLOGJCAL 
MACROMOLECULES UNDER VARIOUS EXPERIMENTAL CONDITIONS 
PHARMACEUTICAL DRUGS 
See Table 1 for legend. 
Phenacctin D 5 Hinson [96] 
N-Hydroxyphenacetin 5 Mulder [182} 
Acetaminophen (=paracetamol) D 3 Hinson [96] 
Labadorios [132] 
Thorgeirsson [271) 
Antipyrine D 3 Tabarelli -Poplaw ski [268] 
Morphine D 5 Deutsch [54] 
Estrone D 1 Jaggi [107] 
Ethinylestradiol D 1 Jaggi (107] 
no r-Eth ynodrel D 5 Chen [32] 
Diethylstilbestrol D 1 unpublished 
Rifampicine D 5 Bolt [9) 
Ri fampicin e-quinone 4 Bolt (9) 
Mycophenolic acid D 4 Nery [189] 
Furosemide D 5 Wirth [286] 
Warfarin D 5 Lorusso [154] 
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TABLE12 
LIST OF CHEMICALS THAT HAVE BEEN TESTED FOR COVALENT BINDING TO BIOLOGICAL 
MACROMOLECULES UNOER VARIOUS EXPERIMENTAL CONDITIONS 
PESTICIDES, ENVIRONMENT AL POLLUTANTS, MISCELLANEOUS CHEMICALS 
See Table 1 for legend. 
Etbylenethiourea 
~-N aphthylisothiocy anate 
~-N aphthylthiourea 
Parathion 
Urethane 
Ethionine 
Saccharin 
Acrolein 
Dioxane 
Carbon disulphide 
3-Methylfurane 
2-(N-ethyl-carbamoylhydroxymethyl)furan 
p 6 
p 3 
p 3 
p 5 
1 
1 
6 
1 
3 
3 
3 
2 
Ruddick [227] 
El-Hawari [60] 
Boyd [16] 
Kamataki [117] 
Lutz [158) 
(CBI rat liver <0.005 
bladder <0.05) 
woo [288] 
Jarvisalo [112] 
Boyd [17] 
taining compounds like aliphatic amines, hydrazines, azoxy and nitro deriva· 
tives, as weil as triazenes. The group of N-nitroso compounds (Table 9) is very 
weil studied for their DNA·binding activity. Among the naturally occurring 
~ompounds (Table 10) are some of the most potent carcinogens. A number of 
pharmaceutical drugs (Table 11) have also been tested, predominantly for their 
binding to protein. Drugs are also found in many of the other groups of related 
chemieals where they are marked with the letter D for cross-reference (Tables 
1-3, 8). It is interesting to note that among thc 150 chemieals listed in Tables 
1-12 there are 30 pharmaceutical drugs that have been found to undergo a 
covalent binding to biological macromolecules. This is not so surprising for the 
anti-cancer drugs which have to interact with the growth control of cells and 
which do this primarily by reaction with DNA. The situation is more critical 
with some of the very widely used analgesics which should be investigated more 
thoroughly because the use of high doses of this group of compounds can last 
for many years. 
Table 12 lists all the compounds which do not belong clearly to any of the 
afore-mentioned groups. It includes pesticides and environmental pollutants 
some of which can also be found in Table 3 with the halogenated chemicals. 
The classification 1-6 has been done according to decreasing predictive 
value for a correlation of binding to carcinogenicity. 
3.2. Coualent binding to DNA in uivo. Calculation of a CBI 
Class 1 comprises of 64 chemieals where a Covalent Binding Index, CBI, to 
DNA in vivo could be calculated. There are class 1 mernbers in all groups of 
chemieals except among the pesticides which have not been studied exten-
sively. These chemieals are compiled in Tables 13-20 with complete reference 
to the literature. 
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TABLE13 
IN VIVO BINDING OF CHEMICALS TO DN A 
CALCULATION OF COV ALENT BINDING INDICES, "CBI" 
The "Covalcnt Binding Index". CBI, is defined as ON A binding per dose, in the units: 
micromole chemical/mole nucleotides 
CBI= -----------------------------
mmole chemical/kg body weight 
If, with methylating or ethylating agents, guanine·7·alkylations were the only data available, this was 
assumed to represent 80% of the total amount of ON A adducts. 
S = species: r =rat 
m = mouse 
h = hamster 
g = gu inea pig 
p = pig 
R = route: 
Time between administration and sacrifice: 
po =oral 
sc = subcutaneous 
ip =intraperitoneal 
iv = intravenous 
ih = inhalation 
pt = skin painting 
h = hours, d = days, w = weeks, m = months, ....... = about equal to/in, 
Org =Organ 
Ab breviations: 
max = maxin;tum binding in time-dependent study 
liv = liver eso = esophagus 
rli = regenerating liver sto = stomach 
lun =Jung int = intestine 
kid = kidney duo = duodenum 
bla = bladder ile = ileum 
tes = testis col = colon 
bra = brain ski :::: skin 
spl = spieen mye = myeloma 
tby = thymus bma = bone marrow 
mam = mammary gland asc = ascites cells 
PCN = pregnenolone-16et·carbonitril 
PB = phenobarbital 
3MC = 3-methylcholanthrene 
BF = benzofiavone 
BHT = butylated hydroxytoluene 
Syn/Antag = synergisms/antagonisms 
ph = after partial hepatectomy 
SULPHONATES, SULPHATES, AZIRIDINES, EPISULPHIDES, MUSTAROS, OTHER HALOGEN-
A TED COMPOUNDS 
Compound s R Time 
Methyl methane- r iv 4h 
sulphonate 
r ip 4 h = max 
r iv 2h 
Ethyl methane- r ip 17 h 
sulphonate 
Myleran (=busulfan) r ip 2h 
m ip 5h 
Dirnethyl sulphate r iv 4h 
Tricthrlene- r ip 2h 
melamine (TEM) 
3 .4·Epithiobutyro- r po 8h 
nitrile 12 h 
Ni trogen mustard r ip 6h 
m ip 
Org CBI 
liv 556 
liv 272 
liv 360 
liv 62 
rli 150 
liv 21 
liv 37 
rli 308 
liv 0.5 
liv 1 
liv 83 
Other Organs. 
Remarks 
16 h: lower 
-kid, lun, bra, >tes 
-bra, int 
-lun, kid 
ph 
-leukemic spl 
<lun, kid 
ph 
multiple injections 
Ref. 
Swann [261) 
O'Connor [194] 
Kleihues [ 120] 
Swann [262] 
Trams [273] 
Broo kes [ 23] 
Swann [261] 
Trams [273] 
unpublished 
Wheeler (284] 
Wheeler [284] 
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TABLE 13 CONTINUED 
Compound s R Time Org CBI Other Organs, Ref. 
Remarks 
Hemisulphur m ip lh liv 525 <leukemic spieen 
rnustard >hepatoma Brookes [ 23] 
Cyclophosphamide r ip 24h liv 62 Harbers [ 86] 
Carbon m ip 12 h liv 51 rat: only RNA Rocchi [221 1 
tetrachloride 
Vinyl chloride r ih 5h liv 525 Bolt [ 10] 
1,2-Dibromoethane r ip 24h liv 180 -kid: >others Hill [95] 
Some recent, so far unpublished CBI from this laboratory have been included 
but arenot discussed in detail in this review. 
1 ,2-Epithiobutyronitrile (Table 13), a5 the first example for the effectiveness 
of DNA binding in vivo of a natural plant constituent containing the three-
membered thürane ring system, the sulphur analogue to the epoxide or the 
aziridine. 
Aflatoxin M1 (Table 19), a metabolite of aflatoxin B1 secreted in the milk 
of cows which have been fed aflatoxin B 1 containing feed. 
Metabolites of aflatoxin B1 bound to the macromolecules of the liver of a rat 
which has been administered [C-14]aflatoxin B1• This study of the 'relay' tox-
icity of a food residue is discussed in section 4.1. 
Diethylstilbestrol (Table 20). DNA bindingwas higher in the hamster than in 
the rat. This corresponds to the observed incidence of tumors. 
3.3. Covalent binding to DNA in viuo. No calculation of a CBI possible 
Class 2 comprises of about 20 compounds which have been shown to inter-
act covalently with DNA in vivo but where either the Iiterature data was insuf-
ficient for the calculation of a C·BI or where the binding was measured at the 
site of administration so that a calculation of a dose per kg body weight is not a 
reasonable means for standardizing. Tables 21-25 Iist these compounds. In 
addition, chemieals of class 1 that have been studied under class 2 conditions 
are repeated, because there are some interesting comparative data on DNA 
binding of related chemieals and comparisons of DN A binding at the site of 
administration after various pretreatments. This is the case for many skin paint-
ings with polycyclic aromatic hydrocarbons, i.e. for many of the very early and 
pioneering experiments. 
3.4. Covalent binding toprotein in vivo 
Protein-binding in vivo (class 3 in Tables 1-12) has been detected with addi-
tional 27 compounds. For many of these it is only a matter of the limit of 
detection that DNA bindingwas not established except for the very unstable 
directly alkylating or ultimate carcinogens that are too short-lived to reach 
DNA. 
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TABLE 20 
IN VIVO BINDING OF CHEMICALS TO ON A 
CALCULATION OF COVALENT BINDING INDICES, 'CBI' 
PHARMACEUTICAL DR UGS, MISCELLANEOUS COMPOUNDS 
Sec Table 13 for legend. 
Compound s R Time Organ Remarks Refercnce 
Estrone r PO 8h liv 1.1 Jaggi [107) 
Ethinylestradiol r po 8h liv 1.5 Jaggi [107] 
Dieth y lstilbestrol r po 8h liv 0.4 kid, spl, lun <0.05 unpublished 
h SC 8h liv 5 kid: 1 unpublished 
r SC 8h liv 0.6 kid: -0.1 unpublished 
Urethane m ip 24 h liv -35 (includes in corpora-
lun -84 tion of labelled Boyland ( 18] 
carbon dioxide) 
m ip 2-24h liv 29 10 h = max Lawson [142] 
m ip 4-16h liv 23 linear dose-dependence, 
less after ph Lawson [143] 
m ip 24 h liv -25 -k.id <Iun Bhide [6] 
m ip 6h liv 90 also: fetal tissues, rli Bhide [7] 
m ip 12 h = max liv 90 Pound [208] 
r ip 24 h liv 37 various sites of Iabel Prodi [213] 
r ip 24 h liv 15 compare mause: 2S Bhide (6] 
Ethionine r ip 18 h liv 0.2 Swann [263] 
r ? 12 h liv 0.7 Rocchi [221] 
Acrolein r ip 0.2-24 h rli 360 stable Munsch ( 183] 
3.5. Covalent binding to nucleic acids or protein in vitro 
In vitro binding studies with incubations of nucleic acids ( class 4) or protein 
( class 5) with a test compound were positive for additional 20 and 22 chemi-
cals, respectively. The metabolic activation to reactive derivatives was per-
formed in most cases with mammalian liver microsomes. This type of test has 
predominantly chemical relevance and a relationship to tumorigenicity must 
remain very vague. 
3.6. Compounds for which no covalent binding to nucleic acids was found 
6 compounds have been tested for covalent binding in vivo to DNA but no 
binding was found. Two non-carcinogenic epoxides and benzo[e]pyrene were 
compared with chemically related, carcinogenic compounds in order to show 
the good quantitative correlation between carcinogenicity and DNA binding. 
Saccharin was studied on an absolute basis and the Iimit of detection of a Cova-
lent Binding Index, CBI, for DNA of rat liver and bladder was 0.005 and 0.05, 
resp. [158]. This is more than a million times below the effectiveness of bind-
ing of aflatoxin Bl and reflects the Iack of Saccharin to undergo covalent inter-
actions with DNA in vivo. The carcinogenicity of saccharin to the bladder of 
male rats ( from the extremely high dosage of 5% in the diet) must therefore be 
due to an indirect, "epigenetic ", mechanism and not to a covalent interaction 
with DNA. 
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TABLE 21 
IN VIVO BINDING OF CHEMICALS TO DNA. NO CALCULATION OF A 'CBI' POSSIBLE 
SULPHONATES, EPOXIDES, LACTONES, MUSTARDS, OTHER HALOGENATED COMPOUNDS 
See Table 13 for legend. 
Compound s R Time Org Remarks Reference 
Methyl methane- r ip 4h liv pattern of methylations Cnddock [ 48] 
sulphonate 
1,2,3,4-Diepoxybutane m pt 12 h = max ski no binding from two non- Paul [199] 
carcinogenic epoxides 
ß-Propiolactone m pt 24 h ski Brookes [24] 
m pt divers ski non-linear dose-response Colburn [35] 
with binding and tumors 
(saturation kinetics) 
m Pt divers ski lower binding in resistant Colburn [36] 
strain 
m pt 4 h = max ski ON A binding high er than Colburn [ 3 7] 
from compounds at bottom 
of Table. Correlates with 
tumor induction 
Nitrogen mustard m ip lh asc linear dose-binding dep. Chun [33] 
Sulphur mustard m ip 0.5 h asc Brookes [ 201 
m ip 4h asc Trams [273] 
AnUine mustard m ip 18 h mye correlation binding vs. Connors [38] 
tumor inhibition 
m SC 30 h asc resistant = sensitive asc. Poynter [209] 
ß-N aphthylamine m ip 18 h;;;;: max mye correlation see above. Connors [ 3 81 
mustard linear dose-binding dep. 
Cyclophosphamide r ip 2 h;;;;: max div time-depend. fluctuations Tew {270] 
Chlorambucil m ip 0.1- 4 h asc Trams [273] 
Vinyl chloride r PO chronic liv after 2-year feeding Green [82] 
lodoacetic acid m pt 4 h = max ski <<protein binding; com- Colburn [37] 
pare: ß-propiolactone 
3-Chloropropionic acid m pt 4 h = max ski <<protein binding; com- Colbum [37] 
pare: ß-propiolactone 
3-Iodopropionic acid m pt 4 h = max ski <<protein binding; com- Colburn [ 3 7] 
pare: ß-propiolactone 
4. Correlation of carcinogenicity with DN A binding 
4.1. Quantitative correlation of CBI for liver DNA wi.th hepatocarcinogenicity 
For the reasons outlined in section 2.3, Covalent Binding Indices, CBI, have 
been determined mostly for the liver not only from hepatocarcinogens but also 
from compounds which do not induce liver tumors. 
In this section, hepatocarcinogens are taken together and a correlation of 
their carcinogenic potency with CBI for liver DN A is discussed. 
A classification according to carcinogenic potency is currently being 
attempted iri many laboratories [ 175]. Am es and coworkers have announced a 
complete Iiterature survey of long-tenn carcinogenicity assays in order to calcu · 
late for each carcinogen a so-called TD-50, i.e., the daily dose needed to induce 
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TABLE 22 
IN VIVO BINDING OF CHEMICALS TO DNA. NO CALCULATION OF A 'CBI' POSSIBLE 
AROMATIC HYDROCARBONS 
See Table 13 for legend. 
Compound s R Time Org Remarks Reference 
Anthracene r 20 h mam injection into mam gland Lin [153] 
Benz[a]anthracene m pt 28 h ski Brookes [24] 
Dibenz [a,c] anthracene m pt 24 h ski = [a,h]-derivative Heidelberger [90] 
no correl. with carcinog. 
m pt 24 h = max ski <[a,h ]-derivative Brookes [21] 
correl. with carcinog. 
m pt 50 h = max ski Goshman [ 79] 
Dibenz[a,h 1 anthracene m pt 24 h ski see above Heidelberger (90] 
m pt 24 h = max ski see above Brookes [ 21] 
m pt 40 h = max ski Goshman [ 79 J 
m pt 24 h ski syn/antag. with 7 ,8-BF, Bowden [15] 
5,6-BF, PB (chapter 5) 
Benzo [a] pyrene m Pt 24 h = max ski Brookes [21] 
7 ,12-Dimethyl- m pt 22 h = max ski Brookes [21] 
benz[a]anthracene m pt 24 h ski Goshman [79) 
m pt 24 h ski equal bind. to satellite Zeiger ( 29 5] 
or main band DN A 
m pt Bh ski Bowden [13] 
DN A adduct as template Bowden [14] 
m pt 24 h ski syn/antag. with 7 ,8-BF, Bowden [15] 
5,6-BF, PB (chapter 5) 
r 20 h mam injection into mam gland Lin [153) 
3-Methylcholanthrene m pt 24 h ski Brookes [21] 
m Pt 24 h Ski Goshman [79] 
a specific tumor in 50% of the animals treated for life. Because of the immense 
experimental variety of long-term bioassays this is a very demanding task, 
especially where an extrapolation is required from a few weeks' feeding study 
to life-long feeding. The TD-50 values span over more than 6 orders of magni-
tude from aflatoxin B1 (lMg/kg and day) to trichloroethylene (1 g/kg and day) 
or saccharin (>5 g/kg and day). The use of such high doses is very questionable 
anyway since (i), an impurity might be responsible for the tumors observed, 
and (ii), the overload of an animal with one compound might Iead to second-
ary changes finally responsible for the development of a tumor. 
In Table 26, we have grouped the hepatocarcinogens into 3 classes accord-
ing to very rough classification on the basis of data available in the "Monog-
raphs on the evaluation of carcinogenic risk of chemieals to man" of the Inter-
national Agency for the Research on Cancer, Lyon, France. As soon as Am es 's 
TD-50 data are available a more refined classification might be possible. The 
CBI were selected from Tables 13-20, and a maximum value was chosen if a 
time-rlependent study was available. A striking quantitative correlation between 
DN A binding and hepatocarcinogenicity is seen with these representatives of 
many different chemical classes. It emerges that a CBI in the thousands repre-
sents the strong hepatocarcinogens, a CBI in the hundreds represents the moder-
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TABLE 23 
IN VIVO BINDING OF CHEMICALS TO DNA. NO CALCULATION OF A 'CBI' POSSIBLE 
AMINES, HYDRAZINES, AZOXY·, AND NITRO-DERIVATIVES, TRIAZENES 
See Table 13 for legend. 
Compound s R Time Org Rernarks Reference 
2-Naphthylarnine m ip 24 h- 7 d liv >kid; correlation with Hughes [97] 
strain susceptibility 
2-Acetylaminofluorene r ip chronic mam no increase beyond 2 w Janss [110] 
4-Dim eth y larninoazo- r po liv 1-3 w in the diet Chauveau [31] 
benzene 
2-Mcthyl-4-dirnethyl- r po liv 1-3 w in the diet Chauveau [31] 
aminoazobenzene correlation of tumor for· 
mation with DN A-binding, 
not protein 
1,2·Dimethylhydrazinc r SC 3h liv >other organs, 0(6)/N-7- Likhachev [ 150] 
guanine methylation higher 
in col than liv 
m SC 6/24 h liv, col 7-methylguanine detccted Hawks [87] 
Cycasin r po 10 h liv non-radioactive; 7-methyl- Shank [240] 
guanine identif. 
Methylazoxymethanol r po 5-lOh liv 7·methylguanine identif.; Shank [240] 
acetate also kid, int 
4-Nitro-quinolinc-1- m ip 1-32 h asc 4 h = max Ikegami [99] 
oxide 
4-Hydroxyamino- r ip lh asc Tada [269] 
quinoline·l-oxide 
l·Nitro-9-(3' -dimethyl- m ip 4 h = max asc Konopa [124] 
n -propylamino )· 
acridinc 
Dacarbazine (DIC) r ip 5h liv also: lun, kid, bra. Skibba [247] 
DN A-methylations 
ate, and a CBI in the tens the weak hepatocarcinogens. The limit of detection 
of a binding to liver DNA has been discussed in section 2.2, and saccharin, a 
clearly non-hepatocarcinogenic compound is more than a million times less 
effective than the strorig hepatocarcinogens. Such a range of 6 orders of magni-
tude was also found with the TD-50 values which is a nice indication that CBI 
and carcinogenicity could be quantitatively related. 
Among the chemieals chosen for Table 26 is aflatoxin M 1, for which only 
rare information is available on carcinogenicity. Aflatoxin M 1 is a metabolite 
of the potent hepatocarcinogen aflatoxin B 1, and is secreted to an appreciable 
amount in the milk of cows which have been fed aflatoxin B1-containing diets. 
Our preliminary binding sturlies have revealed a CBI o'f more than one thousand 
so that aflatoxin M1 must be regarded as a strong hepatocarcinogen. Special 
care should therefore be exerted with aflatoxin contaminations of the feed for 
milk cows. 
Aflatoxin B 1 contaminations in the .feed for meat production represent the 
different problern o"f potential residues in meat. It has been found that a con-
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TABLE 24 
IN VIVO BINDING OF CHEMICALS TO DNA. NO CALCULATION OF A 'CBI' POSSIBLE 
N -NITROSO-COMPOUNDS 
See Table 13 for legend. 
Compound s R Time Org Remarks Reference 
Dirnethylnitrosamine r ip divers liv >kid Magee [160] 
(DMNA) 7-methylguanine, shown Craddock [ 43] 
indirectly with pre· 
feeding of radioactive 
formate 
7-methylguanine in urine Craddock [ 44] 
labelled thymine Craddock [ 4 7] 
other methylations Lawley [136] 
phosphotriesters O'Connor [195] 
phosphotriesters, half- Shooter [243] 
life: 6 w 
· 0(6)-methylguanine 
formation and repair: 
liv versus kid Pt-gg [203] 
Nieoll [192] 
dose-dependent repair Pegg [204] 
m ip liv prefeeding lowers Engelse [ 6 2] 
demethylation of DMNA 
r ip 12 h -8 w liv more persistent after ph Lawson [144] 
or carbon tetrachloride 
Di eth y lni trosamine r PO 3h llv diff. types of alkylation Scherer (230] 
dose-response linear 
for total binding, steep·er 
for 0(6 )-ethylguanine 
Meth y lni trosourea r ip 2-6h liv mitochondrial DN A pre- Wunderlich ( 290] 
ferred 
r iv 1-5 w bra accumulation of 0(6)- Margison [ 16 5) 
methylguanine 
r iv 6h liv Kleihues [122] 
m ip lh liv -bma, > others; impor- Frei [67] 
tance of 3-methyl· 
adenine 
m iv 4 h-7 d liv 0 (6 )-methylguanine 
bra repair equal in strains of Buecheler [ 26 1 
diff. susceptibility 
m ip 2 h-28 d div phosphotriester formation Shooter [242] 
Ethylnitrosourea m ip 2 h-15 w div phosphotriester forma- Shooter [ 242] 
tion; ethylation more 
stable than methylation 
Methylnitrosourethane r po 2-48h liv 7 -m eth ylguanine + others Schoental [234] 
Nitrosomorpholine r ip 28 h liv 6 adducts Stewart [257] 
siderable fraction df an oral dose of aflatoxin B1 is covalently bound to macro-
molecules of the liver of pigs [Lüthy, in preparation]. If this liver is consumed 
by humans the covalently bound aflatoxin derivative might be cleaved from its 
macromolecule in the gastro-intestinal system. It could then be absorbed and 
undergo a second interaction with DNA or other macromolecules of the liver or 
other organs. 
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TABLE 25 
IN VIVO BINDING OF CHEMICALS TO DNA. NO CALCULATION OF A 'CBI' POSSIBLE 
OTHER CLASSES OF COMPOUNDS 
See Table 13 for legend. 
Compound 
Ethionine 
2-(N·Ethyl-carbamoyl-
hydroxymethyl)furan 
s 
r 
r 
r 
m 
g 
r 
R Time 
ip 20 h 
24 h 
24 h 
24 h 
ip 24 h 
Org Remarks Reference 
2 doses Stekol [256] 
abstract Farber [65] 
abstract; 7-ethylguanine in Cox [41] 
all species 
abstract: 7-ethylguanine in Cox [ 41) 
all species 
abstract; 7-ethylguanine in Cox [41] 
all species 
liv model compound for afla- Guengerich [ 85) 
lun taxins 
It would be very important to know the effectiveness of covalent DNA 
binding of such bound aflatoxin derivatives. Wehave performed some prelimin-
ary experiments on this type of "relay" toxicity. Two sponsor rats were orally 
administered about 5 J.LCi [C-14]aflatoxin B1 each. After 6 h, their livers were 
homogenized, centrifuged, dialyzed, and extracted with methylene chloride. 
The dry residue containing about 800 000 dpm macromolecule-bound aflatoxin 
was resuspended in methylcellulose and administered orally to another rat for a 
TABLE 26 
GORRELATION OF HEPATOCARCINOGENICITY OF CHEMICALS IN THE RAT WITH THE 
COVALENT BINDING INDEX, CBI, FOR RAT-LIVER DN A 
The data are selected from Tables 13-20 where also the references can be found. A range of CBI is given 
where similar experiments yiclded widely scattering data. 
Compound 
Strong hepatocarcinogens 
Aflatoxin B1 
Aflatoxin Ml 
Dirnethylnitrosamine 
Dieth ylni trosarnine 
Moderate hepatocarcinogens 
Aflatoxin B2 
2-Acetylaminofluorene 
Vinyl chloride 
a·Aminoazotoluene 
Nitrosopyrrolidine 
Ni trosopiperidine 
Nitrosomorpholine 
Weah hepatocarcinogens 
Urethane 
4-Dimethylaminoazobenzene 
p-Aminoazobenzene 
Ethionine 
Non·hepatocarclnogen 
Saccharin 
Range of CBI 
17 000 
1 600 
6 000 
42-430 
560 
560 
525 
230 
180 
120 
44 
29-90. 
6 
2 
1 
<0.005 
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standard determination of the CBI for liver DNA. No radioactivity was mea-
surable on the liver DNA of this second rat and the highest possible CBI was 
calculated to be about 75 as compared with 10 000 for aflatoxin B •. The corre-
sponding limit of detection of a CBI for rat-liver DNA with tritiated aflatoxin 
B1 was 2.3. It can, at this stage, be concluded that macromolecule-bound 
aflatoxin has a much lower, if any, effectiveness of DN A binding. 
It is evident from Table 26 that CBI and carcinogenicity correlate only semi-
quantitatively. Diethylnitrosamine is too carcinogenic for its relatively low CBI. 
Nitrosomorpholine is also too carcinogenic for its CBI. Vinyl chloride, on the 
other band, seems to have a too high CBI as compared with 2-acetylamino-
fluorene. The weak hepatocarcinogen 4-dimethylaminoazobenzene has a single 
digit CBI which is also obtained froin many other chemieals that do not induce 
liver tumors after similar treatments (benzo[a]pyrene, 3-methylcholanthrene, 
· Table 14). 
This overlapping between the classes can be due to a nurober of causes, 
either resulting from insufficient long-term carcinogenicity data or from prob-
lems with the DNA-binding experiments. Only the latter will be discussed here. 
The CBI calculated from the Iiterature data could be too high if only total 
radioactivity on the DNA was available without appropriate control data on 
biosynthetic incorporation of radioactivity (urethane?) or if the DNA was 
highly contaminated with protein. 
On the other hand, the CBI could be too low if the adduct formed is chemi-
cally unstable and partly breaks down during the DNA-isolation procedure. 
The dose used for a binding experiment was too high so that saturation pro-
cesses and non-linear dose-binding relationships resulted. 
All these factors could reduce the experimental accuracy in the calculation 
of a CBI from the literature. Fortunately, the range of CBI covers about 
6 orders of magnitude and a correlation of CBI to carcinogenic potency can be 
based roughly upon the order of magnitude so that minor experimental devia-
tions do not render a quantifica1ion impossible. More important may be that 
the biological sequence of events between DNA binding and tumor is not the 
same for all bound carcinogens. The most important factors are: various pat-
tems of DNA-binding sites, different activities of DNA repair, different muta-
genicities of a specific type of DNA damage. 
4.2. CBI and organotropy 
4.2.1. Non-hepatocarcinogens and their CBI for liver DNA 
There are physiological compounds which have the biochemical poten-
tial to undergo a covalent binding to DN A in vivo but which are not called car-
cinogens. Estrone (Table 20), for example, has a "Covalent Binding Index" like 
benzene or like the synthetic hormone analogue ethinylestradiol. 
The fact that benzene and ethinylestradiol have similar CBI should not be 
misinterpreted. The CBI was defined as DNA binding per unit dose and it 
should always be bome in mind that the actual dose must also be accounted for 
when a carcinogenic risk has to be assessed. 
It was shown in the last section that a surprisingly good semi·quantitative 
correlation exists between hepatocarcinogenicity and CBI for liver DNA. 
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Similarly, non-hepatocarcinogens would not be expected to bind readily to 
liver DNA. Unfortunately, there are many examples where a CBI for liver DNA 
in the tens or even hundreds is found from chemieals which do not induce liver 
tumors. 
One main group of such false-positive compounds comprises of the directly 
alkylating chemieals like the sulphonates which strongly alkylate liver DN A 
without being hepatocarcinogenic (Table 13). Some nitroso derivatives that do 
not require metabolic activation either, like methylnitrosourea or N-methyl-
N'-nitro-N-nitrosoguanidine (Table 18), belang to the same category. One rea-
son for this discrepancy is the fact that binding data are predominantly from 
parenteral administrations whereas life-long carcinogenicity sturlies are per-
formed with oral intake. The chemieals described above decompose and alky-
late according to their chemical stability primarily at the site of administration, 
which is the oral and intestinal area in long-term sturlies but is the intraperi-
toneal cavity and the liver with i.p. injections. 
This local effectiveness of binding does not, however, explain all discre-
pancies because many of these methylating agents give rise to tumors of the 
nervaus system and of lymphatic tissue which are not at the site of administra-
tion in either carcinogenicity or binding experiment. Furthermore, organo-
tropic carcinogens that require metabolic activation can yield higher DNA 
binding in liver than in the target organ. One example for such behaviour is 
1 ,2-dimethylhydrazine which gives rise to 6X less binding in the colon, the 
target organ, as compared to liver (Table 1 7). 
Biological reasons must therefore also be sought to explain the Iack of cor-
relation nientioned. Some of them are discussed in later sections of this chap-
ter. 
The too high CBI for liver DNA from this type of carcinogen also has posi-
tive aspects: These compounds are moderate or even strong carcinogens! Not 
for liver, as might be expected from the relatively high CBI, but for other 
organs. lt could therefore even be argued that the carcinogenic potency of a 
chemical could be assessed from the binding to Ii ver DN A regardless of the tar-
get organ. This way of thinking diminishes the biological foundation for accept-
ing DNA binding as a prerequisite in chemical carcinogenesis but it strongly 
enhances its value as a short-term test with quantitative predictions but with-
out a value for organotropy. 
4.2.2. CBI for other organs versus carcinogenic organotropy 
As a consequence of what has been said above, the CBI for DNA of the 
target organ is not always higher than that of the liver. Nevertheless, some 
carcinogens which are not hepatocarcinogenic do have high CBI values in the 
target organ. 
Dimethylsulphate (Table 13) yields the highest DNA methylation in brain 
and lung which correlates with the incidence of tumors. Benzo[a)pyrene (Table 
14) gives a higher DNA binding in mause skin than in liver even after oral 
administration. 7 ,12-Dimethylbenz[a]anthracene which gives mostly mammary 
tumors has indeed a much higher CBI in the mammary gland compared to that 
of liver (Table 14). This compound is also known to induce nervous-system 
tumors in the offspring of rats treated at the end of gestation. DNA binding in 
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the brain was indeed more than twice as high in the fetus as compared to the 
pregnant mother, whereas the DNA binding in liver or intestine was higher in 
the mother [57]. The bladder carcinogen O·aminoazotoluene (Table 16) gives 
rise to the highest CBI for DNA of the bladder. 
To summarize, the organotropy of carcinogens can be reflected in high er 
DN A binding in the target organ but this is not a general rule. The following 
refinements of a DN A-binding assay must therefore be included if this aspect of 
chemical carcinogenicity is to be studied more deeply. 
4.3. Refinements in the measurement ofDNA binding for an improved quan-
titative correlation with carcinogenicity 
4.3.1. Pattern of DNA-binding sites 
More than 10 sites of attack on nucleic acids by alkylating agents have been 
detected in recent studies. The formation of some of these products was shown 
not to correlate with carcinogenesis [reviewed in 202]. These included the 
major product of the reaction, 7 -alkylguanine, so that it is not astanishing that 
the measurement of total binding to DNA cannot correlate quantitatively with 
tumor incidence in the class of methylating and ethylating carcinogens. The 
other, more critical products iriclude phosphotriesters, 3-alkylguanine, 0 ( 4 )· 
alkylthymine, 7-alkyladenine, and 0(6)-alkylguanine. This last product has been 
shown to be responsible for mispairing [73,155], and a nurober of investiga-
tions with N -nitro so compounds have revealed that argans which readily 
develop tumors are much less active in the removal of 0(6)-alkylguanine from 
their DNA than non-targetargans [122,138,192,200,201 ,203]. 
The relative abundance of all these DNA adducts depends upon the type of 
chemical reactivity of the ultimate carcinogen. The N-nitroso compounds yield 
positively charged alkyl ions (Fig. 2), i.e. electrophiles which do not strongly 
discriminate among the nucleophilicity of their target atoms (SNl-type reac-
tivity). The sulphonates, epoxides, mustards, and other directly alkylating car-
cinogens (Fig. 2), react according to an SN2 reaction profile where the nucleo-
philic atom on the DNA is actively involved in the attack on the carcinogen. 
Since the N-7 of guanine is the most nucleophilic center, this latter type of 
reactivity Ieads predominantly to 7 -alkylguanine · and comparatively small 
amounts of other DNA damage. With the SNl reactive carcinogens, 7-alkyla-
tion of guanine is still most abundant but the fraction of other positions 
becomes more important. 
On the basis of this knowledge it is no Ionger surprising to see that methyl 
methanesulphonate (Table 13) and methylnitrosourea (Table 18) Iead to about 
the same degree of total DNA methylation in many argans but that the SNl 
reactive nitroso compound gives rise to more tumors, most probably due to a 
higher percentage of methylations at more critical sites than from the SN2 reac-
tive sulphonate. 
For other carcinogens with sterically }arger ultimate derivatives, 7 -alkylation 
of guanine should have more serious consequences than have methylations or 
ethylations. The main DNA adduct with aflatoxin B1, 'for example, is also a 
7-guanine derivative [152] and it is probable that this position has some impor-
tance for the carcinogenic response. This could be due to the fact that large 
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attachments to the double helix interfere not only with the hydrogen bonding 
but also with the tertiary structure. This might be the reason why that surpris-
ingly good quantitative correlation between DNA binding and hepatocarcino-
genicity was found with all carcinogens except the small alkylating chemicals. 
Another reason for the usefulness of measuring total binding lies in the fact 
that some well-studied carcinogens do not at all prefer 7 -alkylation of guanine 
but lead to very specific DNA-binding pattems. 
Aromatic amines were among the first carcinogens for which C-8 of guanine 
was an established DNA-binding site [reviewed in 178]. More recent findings 
suggest that the persistently bound form of 2-acetylaminofluorene results from 
a reaction with the N(2)-amino group of DNA guanine [283 and refs. therein]. 
This amino group seems to be the target also for the ultimate carcinogen of 
benzo[a]pyrene [125, and refs. therein]. 
4.3.2. DNA repair as an organotropic modulating factor in chemical carcino-
genesis. Persistence of DNA binding 
Enzymatic repair of DNA after darnage by physical or chemical means has 
been the object of many studies and has also been reviewed [ 34,146,250]. 
DNA repair is probably one of the most important factors that protects us 
from the consequences of a never-ceasing attack of damaging agents on DNA. 
In a number of recessively inherited human disorders, the affected individuals 
are cancer-prone. 3 of these are associated with defects in the ability of cells to 
repair certain kinds of physical or chemical darnage to their DN A [ 239]. 
From a number of experiments it is now clear that such repair activities can 
also excise s~retches of a DNA strand which contains a nucleotide to which is 
bound an ultimate carcinogen. The following characteristics are quickly sum-
marized [refs. in the first paragraph of section 4.3.1]. 
1. Not all types of DNA darnage are repaired enzymatically or are repaired 
equally weil. 
2. The efficiency of a specific type of repair differs between organs. Slow 
repair correlates with a higher susceptibility of that organ to tumor formation 
from exposure to the agent responsible forthat damage. 
3. Repair activity can be saturated either by a high dose of an alkylating 
agent or by simultaneaus administration of more than one alkylating agent, not 
necessarily of the same type. 
Such DNA repair can be measured on the basis of unscheduled DNA syn-
thesis, but this is possible only with cells in culture where the inhibition of 
DNA replication with hydroxyurea or other compounds is feasible. In intact 
mammalian organs, this approach was so far not successful, and only repair of 
strand breaks can be followed in vivo with DNA-sedimentation analysis. On the 
other band, a time-dependent observation of DNA binding could be used as a 
measure for repair activity, if the appropriate control experiments are per-
formed (2.4). 
The time-dependence of DN A binding reveals striking differences in the per-
sistence of the Iabel in· different organs. There is strong evidence that the target 
organ has a slow repair activity for a specific type of damage. For example, 
DNA binding by 7 ,12-dimethylbenz[a]anthracene (Table 14) in the target 
organ, the mammary gland, decreases only to one third of the maximum Ievel 
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within 6 weeks, whereas in the liver, which is not a target organ und er such 
conditions, no binding can be detected anymore at that time. 
Especially weil known is the persistence of aromatic amines on liver DN A. 
2-Acetylaminofluorene (Table 15) has an almost constant Ievel of binding 
between day 1 and 3, 4-dimethylaminoazobenzene (Table 16) gives rise to per-
sistent binding for even 3 months, o-aminoazotoluene (Table 16) has been 
found bound to liver DNA for almost 3 months. 
As was found in the correlation of hepatocarcinogenicity to DN A binding in 
liver (Table 26), the carcinogenic potency of these aromatic amines and azo 
derivatives of aromatic amines is relatively high for their CBI. This is most 
probably due to the observed persistence of the DNA-bound molecules which is 
a sign of inefficient repair ofthat specific type of darnage in liver DNA. 
The repair activities are therefore not only different in various argans but are 
different also with respect to the various types of DNA damage. This persis-
tence of some types of DNA darnage is astanishing in the light of the experi-
mental fact that repair enzymes can detect conformational disturbances in the 
double helix and cut out tens of base pairs on each side of the damage. It 
could therefore weil be speculated that these persistently bound carcinogens do 
not have only one bond to the DN A but additional, perhaps cross-linking activ-
ity. Such a double interaction can only be performed with big enough mole-
cules with either a second potentially reactive group or a polycyclic system. 
4.4. Mutagenicity of a specific type of DNA darnage 
If DNA with covalently bound carcinogen is replicated or transcri~ed the 
probability for a base substitution, deletion, or insertion to occur will depend 
both upon the exact site of adduct formation as well as on the structure of the 
bound chemical. If one compares a methylating agent with its ethylating 
analogue it is seen that the carcinogenic potencies are similar but that the CBI 
vary by more than an order of magnitude. This discrepancy could arise either 
from less efficient repair of DNA ethylations (section 4.3.2) or from the pos-
sibility that the ethylated DNA gives rise to more mutations upon replication 
than a DNA which is methylated. 
for a refined assessment of the carcinogenic potential of a chemical on the 
basis of DNA binding it would therefore be necessary to study the muta-
genicity of a specific type of DNA damage. Some experimental evidence is 
available for mispairing with 0(6)-methylguanine (section 4.3.1) but there is 
still a considerable Iack of information on the mutagenic effectiveness of larger 
carcinogens bound to DNA. 
Only few reports are so far available where mutagenic events and DNA 
binding have been studied in the sameexperimental system. In the first report 
[ 236] the ethylation of DN A of Drosophila spenn cells was measured and cor-
related with previously published reports on sex-linked recessive Iethals ob-
tained after exposure to ethyl methanesulphonate (EMS). A similar study was 
reported two years later [237] where DNA ethylation of mause spermatozoa 
was measured and discussed with respect to dominant Iethai studies by other 
investigators. · 
Both these studies were pioneering and smoothed the way for additional 
work with more elaborate treatment schedules and more appropriate concen-
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trations of EMS exposure. With these improvements, a linear relationship 
between ethylation of Drosophila sperm DNA and sexMlinked recessive Iethals 
was found in a wide dose range and no threshold was apparent [1]. 
The mause system was also refined and it was found that the ethylations per 
sperm head closely paralleled the dominant Iethai frequency curve for EMS 
[238]. Besides these germ-line studies, only two reports are available with bac-
teria or cells in cul ture. 
In the first one, benzo{a]pyrene and 7-methylbenz[a]anthracene were used 
to mutate Chinese hamster cells, and the binding to cellular DN A was mea-
sured simultaneously [ 191]. The results showed that both carcinogens were 
almost equally mutagenic per corrected micromole per mole nucleotides and it 
was suggested that the difference in carcinogenicity between the two hydro-
carbons is a consequence of the extent rather than the nature of their reaction 
with DNA. 
A nurober of studies have shown that the Ames Test cannot be used for a 
quantification of carcinogenic potential (section 1.2) and it was shown that the 
mairi problern lies in the activation of the carcinogens to chemically reactive 
derivatives. For instance, 7 ,12-dimethylbenz[a]anthracene (DMBA) is a more 
potent carcinogen than benzo[a]pyrene (BP) and is bound to a higher extent to 
DNA in the target tissue, mouse skin (Table 22), as weil as in rat liver (Table 
14). In cantrast to this correlation, the mutagenic activity of DMBA in the 
Ames Test is only about a sixth ofthat of BP [ 172]. This discrepancy could be 
explained if the binding of DMBA to the Salmonella DNA was lower than that 
ofBP. 
In preliminary experiments [ 164] we have incubated Salmonella in liquid 
phase with the two radiolabelled carcinogens in the presence of rat-liver 9000 X 
g supematant. Aliquots were plated and scored for revertants and the bulk 
incubation mixture was used for the isolation of Salmonella DNA and the 
determination of the amount of bound carcinogen. In agreement with Ames's 
data, the mutagenic activity of DMBA was lower than that of BP, and the same 
order was found for the binding to DN A. The low mutagenic potency of 
DMBA is therefore due to low DNA binding, probably because the metabolic 
pathways in the mutagenicity test system are different from those in a mam;. 
malian organ. On the basis of the present results it cannot be decided yet, 
whether the darnage produced by DMBA or BP is equally mutagenic because 
the mutagenicity results scattered widely. 
The experiments described in this section correlate total DNA binding to 
mutagenicity. Obviously, the reservation made on the importance of the pat-
tem of DNA binding holds not only for carcinogenic response but also for 
mutagenicity (see section 4.3.1). It will therefore be important to analyse the 
DNA on a nucleotide level in order to compare the mutagenicities of specific 
DNA adducts with each other. If this can be achieved, a big step towards the 
quantification of carcinogenic potency of chemieals will have been taken. 
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5. Modulations of the carcinogenic response that can be studied on the basis 
of DNA binding 
5.1. Pretreatments and their influence on DNA binding in vivo and carcino-
genicity 
An appreciable number of reports are available on synergisms and antago-
nisms in chemical carcinogenesis [reviews 64,232,281; nutritional influences: 
292]. Much less is known about the influence of a pretreatment on DNA bind-
ing in vivo. 
TADLE 27 
EFFECT OF PRETREATMENT OF ANIMALS ON IN VIVO DNA BINDING AND TUMOR FORMA-
TION FROM EXPOSURE TO CHEMICAL CARCINOGENS 
Sp = Species; r = rat, m = mouse 
Tum =Tumor; liv = liver, ski = skin, fsto = forestornach, - = slightly, kid = kidney, col = colon, div = 
divers. 
Carcinogen Sp Tum Pretreatment Effect an Reference 
Tumor Binding 
Dibenz[a,h]anthracene m ski phenobarbital lower equal Bowden (15] 
5,6-benzoflavone -lower -lower Bowden [15] 
7 ,8-benzoflavone high er equal Bowden [15] 
Benzo [a] pyrene m fsto disulfiram lower lower Borchert [12] 
7 ,12-Dimethylbenz- m ski phenobarbital -lower -lower Bowden [15] 
[a 1 anthracene 5,6-benzoflavone -lower -lower Bowden [15] 
7 ,8-benzoflavone lower lower Bowden [15] 
2-Acetylamino- r liv phenobarbital lower lower Matsushima (170] 
fluorene lower lower Mushlin [ 184] 
3-meth ylcholanthrene lower lower Irving [1 0 2] 
lower -lower McGregor [ 1 7 4] 
special grain diet high er high er Irving [1 0 21 
butylated hydroxytoluene lower lower Goodman (78] 
chloramphenicol lower lower Matsushima (169] 
acetanilide lower lower Matsushima [169] 
n1-acetotoluidide lower lower Matsushima [169] 
indole lower lower Matsushima [169] 
no such correlation with protein 
4-Dimethylamino- r liv phenobarbital lower lower Decloitre [53] 
azobenzene 3-methylcholanthrene ip lower high er Decloitre [53] 
3-methylcholanthrene diet lower equal Decloitre [53] 
high riboßavin diet lower lower Dingman [55] 
1,2-Dimethyl- r div disulfiram lower lower Swenberg [ 264] 
hydrazine r liv aminoacetoni trile ? lower Pegg [205] 
kid ambloacetonitr.Ue ? lower Pegg {205) 
col aminoacetonitrile ? lower Pegg [205] 
3,3-Dimethyl-1- r div protein-free diet ? lower in liv, kid 
phenyltriazene higher in other organs 
Kleihues [123] 
Dim ethy lnitro'samine r liv pregnenolone-16a-car- ? equal Kleihues [121 1 
bonitrile equal Grandjean (80] 
hypophysectomy lower lower Lee [145] 
Methylnitroso- r liv stress-inducing hormone ? high er Magin (162] 
urea 
Aflatoxin B 1 r liv phenobarbital lower lower Garner [72] 
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As was shown in Fig. 1, binding to DNA is a very early event in the chemical 
induction of a tumor. A large number of factors can influence the steps which 
lead to DNA binding [74], an· equally large number of factors can modulate the 
response of the animal between DNA binding and the manifestation of a 
tumor. 
The first group of modulatory factors can fully be studied with a binding 
assay, the second group is beyond the reach of this experimental set-up. In this 
chapter, those modulatory factors are discussed that have an influence on DNA 
binding, chapter 6 will show where a DNA-binding assay cannot give an answer 
to synergisms or antagonisms in chemical carcinogene-sis. 
Table 27 compiles the relatively few experiments where an influence of a 
pretreatment of an animal was measured on in vivo DNA binding in the target 
organ and where the corresponding effect on the tumor incidence is also 
known. There is a very good correlation between the two end-points, thus again 
strongly indicating the cause and effect relationship between DNA binding and 
carcinogenicity. 
The carcinogens investigated comprise of aromatic amines and an azo deriva-
tive, polycyclic aromatic hydrocarbons, N-nitroso compounds, 1,2-dimethyl-
hydrazine, a triazene and aflatoxin B1, i.e. they give a wide selection of the 
known classes of organic chemical carcinogens. 
The pretreatments can be grouped very roughly into the following categories 
which will also be discussed in this order: enzyme inducing agents (section 5.2), 
antioxidants (5.3), and effects of special diets, hormones, surgery, as much as 
they affect DNA binding (section 5.3). 
A larger number of reports is available on the effect of a pretreatment of an 
animal on the binding of a carcinogen to DN A or other macromolecules in an 
in vitro incubation system. These experiments have much less relevance to the 
problern of carcinogenicity because of a major Iack of inactivating pathways 
and intracellular compartmentation. The problems associated with such in vit:ro 
situations have already been discussed in several places and a nurober of experi-
ments were cited in section 2.1 where the in vitro binding showed exactly the 
opposite of the in vivo findings. Due to this Iack of correlation, in vitro binding 
TABLE 28 
EFFECT OF PRETREATMENTS OF ANIMALS ON THE BINDING OF CHEMICALS TO DNA IN IN 
VITRO INCUBA TION SYSTEMS 
Selection of references 
Carcinogen System Pretreatment Effect Reference 
Benzo [a] pyrene rat-liver nuclei 3-methylcholanthrene high er Jernstroem [113] 
high er Rogan [222] 
DNA + mouse- butylated hydroxy- lower Speier [253,254] 
Uver microsomes anisole 
Benzo[a)pyrene and 7,12- epidermal butylated hydroxy- lower Slaga [248) 
dimethylbenz [a] anthracene homogenate toluene and ·anisole 
Aflatoxin 8 1 DN A of rat-liver phenobarbital lower Neal [186) 
slices 
3 '·Methyl-4-d.imethylamino- DN A + rat-liver portacaval shunt lower Ricco [219) 
azobenzene micros. 
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assays were not searched for very thoroughly, and Table 28 gives only a short 
survey of t~e chemieals and carcinogens so far involved in this type of study. 
5.2. Enzyme-inducing agents 
· The formation of the chemically reactive ultimate carcinogen is dependent 
upon the activity of the enzymes involved in this process. Induction of these 
activities is a widely used tool for the modification of the response to a car-
cinogenic stimulus. The best known inducing agents are phenobarbital (PB) and 
3-methylcholanthrene ( 3MC) and they have also been used in many experi-
ments compiled for Table 27. 
It is known that pretreatment with phenobarbital decreases the incidence of 
tumors from 2-acetylaminofluorene (AAF) and a similar decrease was found 
for the binding to rat-liver DNA. Pretreatment with 3-methylcholanthrene also 
inhibits liver carcinogenesis by AAF but not by N-hydroxy-AAF, and, indeed, 
a reduction was found for DNA-bound AAF but not for DNA-bound N-hy-
droxy-AAF. 
Hepatocarcinogenicity by aflatoxin B1 (AFB 1) is reduced by phenobarbital 
pretreatment and so is the binding· of AFB 1 to liver DNA. In cantrast to this 
correlation in vivo, there is an increased formation in vitro of the ultimate car-
cinogen aflatoxin B 1-2,3-oxide if liver microsomes from phenobarbital-pre-
treated rats are incubated with AFB 1 as compared with those from untreated 
rats. 
Similar sturlies have been performed with azo dyes. The inhibitory effect of 
phenobarbital on carcinogenesis by azo dyes could be shown to correlate with 
DNA binding of 4-dimethylaminoazobenzene (still Table 27 for refs.). A similar 
influence of pretreatment with 3-methylcholanthrene on carcinogenesis and 
DN A binding seemed to depend strongly on the route of administration and 
the duration of the pretreatment, and only inconclusive correlations have so 
far been established. 
In the case of these aromatic amines and aflatoxin B1 it is therefore the rule 
that pretreatment with an enzyme inducer decreases tumor incidence and DNA 
binding. With polycyclic aromatic hydrocarbons, however, the situation seems 
more complicated and either increasing or decreasing effects were observed 
(Table 27). This is probably due to the fact that most polycyclic hyd:rocarbons 
undergo a multiple-step activation whereas the former examples need only one 
enzymatic step to form the ultimate carcinogen. 
An additional complication arises in that these activating enzyme systems are 
located not only in the endoplasmic reticulum ( microsomes) but also in the 
nuclear envelope. This latter activity - although much lower - might play an 
important role for DNA binding because of its closeness to this target. 
In this Iabaratory, we have studied the influence of several enzyme inducers 
like phenobarbital, 3-methylcholanthrene and dieldrin on aryl hydrocarbon 
hydroxylase activity (AHH) in rat-liver microsomes and nuclei, and their effect 
on liver-DNA binding of benzo(a]pyrene (BP). It was found that an induction 
of microsomal AHH activity gives rise to increased binding whereas induction 
of nuclear AHH went parallel with a decrease of DNA-bound BP [277]. If the 
relative induction is equal in both cellular compartments, the increasing 
influence of the microsomes outvalues the decreasing effect by the nuclei. 
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These results were in cantrast to our working hypothesis, i.e., that an induction 
of the nuclear AHH should have an increasing effect on the binding to the 
nearby DNA. Additional work will be necessary to spot the other critical 
parameters- enzymatic or not- that modulate the metabolic pathways of BP 
that generate the ultimate carcinogen(s). · 
5.3. Antioxidants, special diets, hormones, surgery 
Antioxidants are widely used food additives and are therefore of special 
iQterest in their modifying effect on chemical carcinogenesis. To this group 
belong butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), 
some benzoflavones, vitamin C, disulfiram, and also the related chemieals vita-
min A and other retinoids. In most cases, their influence on carcinogenicity is 
inhibitory. Caution must however be exerted not to become too optimistic 
about antioxidants in the diet because there is an example where the carcino-
genic activity of dimethylnitrosamine or diethylnitrosamine was shifted from 
the liver to other argans under the combined treatment with disulfiram [233]. 
This antioxidant has probably led to a prolonged presence of unmetabolized 
nitrosamine in the blood so that argans other than the liver increased their 
activity with respect to the oxidation of the carcinogen. In another report on 
2-acetylaminofluorene (AFF)-induced hepatic tumorigenesis in the rat it was 
shown that butylated hydroxytoluene, fed after the carcinogen, enhanced the 
incidence of liver tumors by a factor of about 4 [ 206]. 
A small number of reports are available on the effect of antioxidants on 
DNA binding in vivo (see Table 27 for refs.) and a reduction was indeed found 
in all cases examined. 
BHT decreases_ AAF-induced hepatocarcinogenesis and it was also shown to 
reduce the binding of the carcinogen to rat-liver DNA. Benzo[a]pyrene is car-
cinogenic to the mause forestarnach after oral intubation. No tumors occur if 
1% disulfiram is added to the diet. This inhibition is paralleled by a 2-fold 
reduction of BP binding to DNA and a 6-fold reduction to RNA of the fore-
stomach. Dietary pretreatment of rats with disulfiram also prevents 1,2-dimeth-
ylliydrazine-induced colon carcinogenesis and was found to reduce DN A alkyla-
tion to less than 1% of that detected in animals treated with 1,2-dimethyl-
hydrazine alone. 7 ,8-Benzoflavone (7 ,8-BF) and 5,6-BF are synthetic isomers 
related to naturally occurring flavonoids, some of which have antioxidative 
properties. 5,6-BF is also an inducer of mouse-skin aryl-hydrocarbon hydroxyl-
ase activity whereas the 7 ,8-isomer inhibits this activity. Administration of 
these two compounds in generallowered skin-tumor formation and DNA bind-
ing from 7 ,12-dimethylbenz[a]anthracene or dibenz[a,h]anthracene, except 
that 7 ,8-BF increased the skin tumor incidence from benzo[a]pyrene. lt there-
fore seems difficult to discuss a simple mode of action because both compounds 
interfere with the carcinogenicity on a number of different levels, antioxida-
tion, enzyme induction, and possibly others. Such a multiplicity of effects is 
also expected from the high riboflavin diet which lowered hepatocarcinogenic-
ity and DNA binding from 4-dimethylaminoazobenzene (Table 27). 
What the experiments cited so far have in common is that the amount of 
reactive metabolite of a carcinogen is affected by the pretreatment, either by 
changing the activity of metabolizing enzymes or by trapping the ultimate car-
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cinogen with antioxidants. To this same group of experiments belong pretreat-
ments with special diets, e.g., grain diets. In such studies, the activity of detoxi-
fying enzymes, such as glutathione-S-transferase is reduced because of a gluta-
thione deficiency. It is therefore not surprising that the concentration of reac-
tive metabolites near the DNA is increased, and that higher DNA binding 
occurs (2-acetylaminofluorene, Table 27). The effect of a protein-free diet on 
guanine-7 -methylation by 3,3-dimethyl-1-phenyltriazene (Table 27) seems to 
be more com plicated because a marked difference between the liver or kidney 
and the other argans was found. ' 
Table 27 also lists 3 reports on the effect of a pretreatment with hormones 
or steroid analogues on DNA binding. With methylnitrosourea it was found 
that pretreatments of rats with stress-inducing hormones like adrenaline and 
hydrocortisone enhanced the methylation of liver DNA and RNA. Pregneno-
lone-16~-carbonitrile (PCN), a hormonally inactive steroid inhibits the acute 
toxicity of dimethylnitrosamine yet does not affect its overall metabolism in 
vivo. Methylation of liver DN A by dimethylnitrosamine is also unaffected by 
such a pretreatment. The same was found in another Iabaratory and it was con-
cluded that PCN can provide protection against the hepatotoxic effects of 
DMNA without reduction of the Ievel of alkylation. 
Surgery has also been studied for its effect on carcinogenicity. Such experi-
ments belang, in principle, to the next chapter because they affect primarily 
the cell-division rate as a modulator of carcinogenesis which cannot be studied 
on the basis of DN A binding. One experiment has .been reported, however, 
where it ·was shown that a portacaval shun~ lowered the incidence of liver 
tumors in rats treated with 3' -methyl-4-<limethylaminoazobenzene. A parallel 
reduction of DN A-bound carcinogen led to the assumption that the contribu-
tion of the liver to the metabolism of the carcinogen was lowered due to the 
shunt so that extrahepatic organs increased their share in the drug metabolism. 
In short, there is an excellent correlation between DNA binding in vivo and 
tumor incidence after a number of pretreatments and it is obvious that the 
measurement of DNA binding is a potent tool in the study of the mechanisms 
which govem the activation-inactivation processes with organic carcinogens. 
5.4. Effect of dose and doseseheduZe on the CBI 
5.4.1. Dose-binding relationships 
With radiolabelled compounds of high specific activity it is possible to mea-
sure a DNA binding from a dose which is orders of magnitude below those nor-
mally used in long-term bioassays on carcinogenicity. In the latter experiments, 
the limited nurober of animals requires an unnaturally high dosage for the 
induction of a statistically significant number. of tumors. The highest dose is 
often chosen at the Iimit tolerated by the animals so that non-toxic compounds 
like saccharin can be tested at unrealistically high Ievels where, eventually, 
secondary effects might Iead to tumors. 
For the calculation of a CBI the DNA binding is divided by the dose adminis-
tered with the implicit assumption that there is a linear dose-binding relation-
ship. For the reasons outlined in section 2.3.2 this does not have tobe the case 
and the CBI obtained from a high dose necessary for a suitable Iimit of detec-
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tion of a binding might not be the same as the one from a much lower, environ-
mental exposure. 
Dose-binding relationships have therefore been performed with a nurober of 
carcinogens listed in Tables 13-20. 
With benzo[a]pyrene (Table 14) a non-linear relationship was found in a 
dose range of 40 }.lg/kg to 4 mg/kg, with a sigmoid step between 1 and 2 mg/ 
kg. The non-linearity was attributed to an induction of the activating enzymes 
which, indeed, starts from a single intraperitoneal dose of 2 mgjkg [ 159]. 7,12-
Dimethylbenz[a]anthracene (Table 14) gave the same CBI for liver DNA from 
doses of 120 }.lg/kg or 25 mg/kg, but the dose-binding relationship between 
these two points is not known. o-Aminoazotoluene (Table 16) gave rise to a 
linear dose-binding response from 12 to 108 pg per mause. The binding of 
trans-dimethylaminostilbene (Table 17) to rat-liver DNA also increased linearly 
with doses ranging from 0.025 to 2.5 pmol/kg, plateauing-off beyond that 
dose. The CBI of 1 ,2-dimethylhydrazine (Table 17) decreases about 4-fold after 
an increase of the dose by a factor of 50. Dirnethylnitrosamine (Table 18) 
showed a linear dose-binding relationship from doses of 1-27 mg/kg, and also 
urethane (Table 20) had a constant CBI for mouse-liver DNA within a 10-fold 
dose range. 
This evidence of linear dose-binding relationships with compounds of many 
different chemical classes makes it clear that a measurement of a dose-binding 
relationship will not, a p~ori, be required for short-term testing of chemieals 
with a DN A-binding assay in vivo. The rare non-linearities cited are small, as 
compared with the order of magnitude which determines the carcinogenic 
potency of a chemical. If, however, an extrapolation of high-dose data from a 
long-term bioassay to lower dosage is attempted, a dose-dependent DNA-bind-
ing assay might weil be the method of choice. 
5.4.2. Dose-schedule 
Most experiments where a CBI has been determined are on the basis of a 
single administration as discussed in section 2.3.2. Pretreatments of the animals 
with the carcinogen, i.e. a simulation of chronic exposure, has been performed 
on rare occasions with very interesting results. 
With dimethylnitrosamine (Table 18), a pretreatment did not clearly change 
the total amount of DNA binding in liver or kidney but it resulted in a drastic 
build-up of 0(6 )-methylguanine in kidney, the target organ from that schedule. 
This experiment therefore revealed the overload of the DNA-repair activity in 
kidney after repetitive exposure. This important result would not have been 
found from a single administration. 
Prefeeding of mice with o-aminoazotoluene (Table 16) gave rise to a 4-fold 
decrease in the CBI for liver DNA but not for protein. The reason for this is 
not entirely clear, nor is its effect on the tumor formation. 
These two examples show that prefeeding might be a valuable tool for the 
elucidation of biological responses to repetitive or chronic exposure to carcino-
gens. 
5.4.3. More than one carcinogen at a time 
We are not aware of any report on the in vivo alkylation of DNA from the 
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simultaneaus adminis'tration of two or more radiolabelled carcinogens although 
this approach 'might be very valuable for the understanding of synergisms and 
antagonisms in chemical carcinogenesis. We are in our environment constantly 
exposed to a nurober of carcinogens and it is surprising how rare reports on the 
cumulative effect of carcinogens are. One main reason for this Iack of informa-
tion is that the work involved in long-term tests is already big enough with the 
single chemieals so that it is impossible to study the multiple combinations of 
carcinogens with such bioassays. The study of DNA binding and repair could 
well be a valuable approach to this type of problem. 
Nice experiments have been reported where rats were pretreated with a nuro-
ber of carcinogens. Their effect on the methylation of guanine at position 7 
and 0(6) by methylnitrosourea was then studied. It could be demonstrated 
that the excision-repair system for 0(6)-methylguanine in rat liver can be over-
loaded and requires several days to recover and restore its initial capacity 
[122]. 
6. Modulatory factors in chemical carcinogenesis which cannot or not com-
pletely be studied on the basis of DNA binding 
6.1. Modulations of the events between DNA binding and tumor 
Between the covalent binding of a carcinogen to DN A and the manifestation 
of a tumor there are many steps which contribute to the final response of the 
animai·to the carcinogenic stimulus. A nurober of these steps, like. DNA repair 
or the mutagenicity of a specific DN A adduct, can in principle be studied with 
binding experiments (sections 4.3 and 4.4), but there is thereafter a sequence 
of biological events which cannot be studied on the basis of DNA binding. How 
these steps are modulated and what the consequences are for the process of 
tumor formation is outlined in the next sections. 
6.1.1 Mitotic activity 
A DNA darnage can only then be responsible for a heritable change when a 
DN A replication leads to a mutation before the darnage is repaired. Mitotic 
activity is therefore of prime importance and all secondary influences which 
aceeierate cell division are likely to increase the susceptibility to a carcinogenic 
stimulus. This has clearly been shown with partial hepatectomy (referred to as 
"ph'' in the Tables) where the liver, in its regenerating phase, is much more 
prone to develop cancer [ 49,50], even from carcinogens that do not normally 
attack the liver. Small bowel resection also. enhances carcinogenicity by 1 ,2-
dimethylhydrazine and azoxymethanol [197]. Similar but not so drastic effects 
can be obtained after necrotic alterations of the liver, e.g., with carbon tetra-
chloride [ 144] , or with drugs that stimulate cell division like pheno barbital and 
other synthetic or naturally occuning substances. 
Phenobarbital has already been discussed as an enzyme inducer but it is also 
a mitotic stimulant. It can therefore affect carcinogenicity on various Ievels and 
we have the complicated situation that a pre-treatment of rats with phenobar-
bital reduces hepatocarcinogenesis of 2-acetylaminofluorene by changing the 
metabolic pathways, whereas it increases the tumor incidence if it is given after 
the carcinogen and acts as a cocarcinogen probably on cell division. 
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Mitotic activity is governed primarily by the organ itself, by the function and 
life-time of its c~lls. At a first glance, one would think that rapidly dividing cell 
populations like bone-marrow stem cells, intestinal epithelia, skin and germ-line 
cells would be most suscepti'ble to chemical carcinogenesis [reviews on these 
problems: 27,28]. This is only partly true because these argans are very limited 
with respect to drug activation and metabolism, and some have very active 
DNA repair. 
6.1.2. Promotersandhormones 
A related group of compounds, termed "promoters ", do not cause cancer by 
themselves. They were first discovered for their ability to promote the growth 
of skin tumors in mice which had been treated with doses of carcjnogens too 
low to induce tumors on their own. These phorbol derivatives were for a long 
time regarded as mitotic stimulants (see above) but recent experiments show 
that promoters might affect the differentiation of cells and it has been sug-
gested that this type of substance may keep mutant cells alive, prevent them 
from differentiation ( which would ultimately Iead to cell death) until enough 
mutations have occurred that they can survive to form tumors. 
Hormones form a groilp of chemical carcinogens and teratogens with a con-
troversial mode of action. We have been able to show a weak covalent binding 
activity of estrone, ethinylestradiol and diethylstilbestrol to liver DN A in vivo 
(Table 20). Their carcinogenicity could therefore weil be based upon their 
chemical reactivity. On the other band, most of the tumors associated with 
hormones are tumors of the target argans of their hormonal activity so that 
their carcinogenicity might also be due to mitotic stimulation or promoting 
activity. There is as yet no conclusive evidence for the more important mode 
of action. 
6.1.3. Probability of transformation. Immunology 
Another critical point in the development of a chemically induced tumor is 
the probability that a mutation or a nurober of mutations leads to cell death or 
to what is termed "transformation ", i.e., lass of growth control and invasive 
growth characteristics. Although we do not know of any experimental data it is 
conceivable that different argans and different stages of cell differentiation 
might also have an influence on the ease with which a transformation can 
occur. lt is clear that such aspects will never be elucidated with DNA binding as 
an indicator in the process of chemical carcinogenesis. 
A critical review is available on the influence of the immune system in cancer 
research [ 259]. It would not be wise to discuss these very complicated interac-
tions in this review. Suffice it to say that immunological influences m ust also 
play a role in cancer formation and ~treatment and that these modulatory 
factors are far beyond the reach of a DNA-binding experiment. 
6.2. Whole-system responses 
6.2.1. Susceptibility of various species 
It is weil known that the carcinogenic activity of many compounds is spe-
cies-specific, and there is a nurober of experiments available where DNA bind-
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ing has been determined in susceptible and non-susceptible species. In most 
cases, there is a qualitative correlation between DNA binding and susceptibility. 
On a quantitative basis, however, the observed differences in DNA binding are 
often too small to account for the total difference. It must therefore be con-
cluded that the species differences are based partly on differences in the steps 
leading to DNA binding ,and partly on differences in the events between DNA 
binding and tumor formation. The following examples might Blustrate this 
situation. 
Carbon tetrachloride (Table 13) is hepatocarcinogenic for mice but much 
less so for rats, and liver-DN A binding was indeed detected only in the mouse. 
Benzo[a]pyrene (Table 14) is more effective on the skin of mice than of rats, 
and the binding to DNA of mouseargans is generally higher than in the rat, 
possibly because of the higher activity of epoxide hydratase in the latter spe-
cies. Aflatoxin Bl (Table 19) is strongly hepatocarcinogenic for the rat, much 
less so for the hamster or the mause. The same difference is found with DNA 
binding. Diethylstilbestrol increases the incidence of tumors in argans which 
are targets for its activity as a hormone. The male hamster develops, in addi-
tion, kidney tumors. This special susceptibility of the hamster was also seen 
with respect to DNA binding (Table 20). 
No such correlation was found in the following examples: 4-dimethylamino-
azobenzene (Table 16) is hepatocarcinogenic for the rat but not for the guinea 
pig. The binding to DNA is about the same. Treatment of rats, mice and guinea 
pigs with ethionine (Table 25) yielded 7-methylguanine from liver DNA in all 
species although only the rat is susceptible to the hepatocarcinogenic activity 
of this compound. 
6.2.2. Different susceptibility of strains 
The differences in the susceptibility of various strains to a carcinogen can be 
quite as striking as between different species. The following examples show 
that this variability cannot be assessed with the measurement of DNA binding 
as weil as was possible with different species. It seems more likely that the 
strain differences are due to the steps between DNA binding and tumor forma-
tion. 
The covalent binding of 3 polycyclic hydrocarbons to DNA was studied in 
the skin of mice of different strains. The Ievel of binding did not show a cor-
relation with the reported susceptibilities of the 3 strains [ 207] . Methylation 
of lung and liver DNA was studied in two inbred strains of mice with widely 
different susceptibility to tumor formation by dimethylnitrosamine (Table 18). 
No strain differences could be demonstrated in the total amount and time 
course of DNA methylation. It has been discussed before that total methyla-
tion might not be the correct means of assessing 'DN A darnage because of the 
widely varying consequences of the different sites of alkylation. In favour of 
the above experiment it can however be said that the pattem of DNA binding 
should be the same in both strains. Furthermore, a similar experiment was per-
formed where 0(6)-methylation was measured from methylnitrosourea (Table 
24) in two mouse strains with different susceptibility to the formation of brain 
tumors. It was found that total DNA binding, 0(6)-methylation of guanine and 
0( 6 )-methylguanine repair were very similar in the brain of both strains. In the 
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liver, which is an equally good target for both strains, there was a distinct dif-
ference in total methylation and the rate of 0(6)-methylguanine removaL 
Positive correlations between DNA binding and differences in susceptibility 
of different strains are also available, e.g. for the binding of ß-propiolactone 
(Table 21) to skin DNA of 2 strains of mice, for 2-naphthylamine (Table 23) 
where the binding to liver DNA of 2 strains of mice correlated with the cor-
responding susceptibility to hepatic tumor formation. With 1,2-dimethylhydra-
zine, the low carcinogenic response of C57BL/Ha mice seems due to the smaller 
extent of initial methylation of colon DNA as compared to a more susceptible 
strain [ 40]. With trichloroethylene, in vitro binding to microsomal protein 
(DNA was not examined) correlated with the susceptibility of these strains of 
mice [4]. 
6.2.3. Differences from sex and age 
Differences are also found with respect to the sex of the animals. We are 
aware of one example where this is reflected by the in vivo DNA binding. 1' -Hy-
droxysafrole (Table 19) is moderately hepatocarcinogenic for female mice but 
only weakly formales. This difference is evident from liver-DNA binding with 
CBI of 280 for females and 5.5 for males. 
Cases are known where the susceptibility to a carcinogenic stimulus is depen-
dent on the age of the animal. 7,12-Dimethylbenz[a]anthracene (Table 14) 
induces mammary tumors most readily if the female rats are about 50 days old. 
Binding of the carcinogen to DNA of the mammary gland was highest in ani-
mals of this age as compared with 35- or 120--day old ones and it persisted for a 
Ionger time. 
The examples discussed in this section show that DNA binding is a necessary 
but not sufficient event in the induction of a tumor by a genotoxic organic 
chemical. The differences in the susceptibility with respect to species, strain, 
sex and age can therefore only partly be based on differences in the binding to 
DN A of the target organ. Species differences are relatively well followed with 
DN A binding whereas the experimental evidence with various strains indicates 
that the reasons foradifferent susceptibility rather lies between DNA binding 
and tumor formation. 
7. Conclusions 
The most probable mechanism of tumor initiation by genotoxic carcinogens 
involves the covalent binding of the compound or one of its metabolites to 
DN A of the target organ. 
This D NA binding can be measured in intact mammalian organisms with the 
use of radioactive chemieals in a low dose range which would be ineffective in 
the standard long-term bioassay on carcinogenicity. Dose-response relation-
ships for DNA binding in vivo provide a useful approach for the extrapolation 
from the high dosage of long-term bioassays to lower doses. 
The determination of "Covalent Binding Indices", CBI, might be a valuable 
tool in the quantification of the potency of a genotoxic chemical carcinogen. 
This was shown by the correlation of hepatocarcinogenic potency with CBI for 
liver DNA. Short-term tests based on mutagenicity data do not yield a similar 
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quantitative correlation with carcinogenicity. A number of compounds, such as 
nitrosamines, 1,2-dimethylhydrazine, methylazoxymethanol, carbon tetrachlo-
ride, or urethane, are by orders of magnitude less mutagenic in the Ames test 
than "expected" from carcinogenicity data. 
The quantitative correlation of DNA binding with carcinogenic potency can 
be improved if two important aspects are included in the evaluation: (i) the 
persistence of DNA-bound chemical and (ii) the probability for a mutation to 
occur. 
(i) A carcinogen-induced DNA-DNA mispairing can only occur if the darn-
age is not repaired before the DNA is replicating. DNA-repair capabilities and 
mitotic activity are therefore important organ-specific parameters which can 
be evaluated in part in separate experiments, e.g., with a time~dependence of 
DNA binding. 
(ii) The probability for a mutation to occur when damaged DNA is replicat~ 
ing depends both upon the exact site of DNA binding as weil as on the struc-
ture of the chemical bound. This probability can be estimated from an experi-
ment where mutagenic events are scored simultaneously with a determination 
of the binding of the carcinogen to the DNA of the mutagenicity test system. 
The most reliable quantification of a carcinogenic potency on the basis of 
DNA binding is obtained when structurally related compounds are compared 
with each other. It can, in such a case, be assumed that persistence on the DNA 
and mutagenicity of the DNA adduct do not differ much. 
A nurober of pretreatments of animals have been shown to change the inci-
dence of tumors from a chemical carcinogen. This is in most cases due to 
changes in the activating/inactivating pathways for the c-arcinogen. Generally, 
DNA binding in vivo paralleled the observed effect on tumor formation. DNA 
binding can therefore be a fast and useful indicator in the study of influences 
of various types of pretreatments on the tumor incidence. 
Limitations for a DNA-binding assay: 
Radioactively Iabelied chemical must be available for a DNA~binding assay 
in vivo. 
Organotropy of chemical carcinogens cannot be based quantitatively upon 
the measurement of DN A binding alone. 
Differences in the susceptibility of species, strains, sex or age towards chemi-
cal carcinogens can only partly be explained on the basis of D NA binding. 
Factars which affect the biological sequence of events between DNA binding 
and tumor formation cannot be assessed with a binding assay. These include 
mitotic stimulants, promoters, hormones, immunological changes. 
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